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Freezing of gait (FOG) is experienced by a signiﬁcant number of patients with Parkinson’s disease (PD). The pathophysiology of
this disabling motor symptom remains unclear, and there are no eﬀective therapies. Anxiety has previously been posited as a
contributing factor to gait freezing. There have been few studies directly investigating this topic, and a comprehensive literature
review is lacking. The objective of this paper was to systematically review the evidence associating anxiety with the presence,
severity, and progression of FOG in PD patients. The PubMed, EMBASE, and PsycINFO databases were searched up to September
19, 2018, for English-language, peer-reviewed articles that explored anxiety and FOG as outcome measures in a PD population
base. Review articles, case reports, and articles that assessed gait disorders other than FOG were excluded, yielding a total of 26
articles in the ﬁnal analysis. Of these 26 studies, 16 had a signiﬁcant relationship between anxiety outcome measure and either
presence or severity of FOG. There was great variability among studies in terms of outcome measures for both FOG and anxiety.
Despite this heterogeneity, most studies relate anxiety and FOG. Standardized, high-validity outcome measures of anxiety and
FOG are needed. Future exploration should aim to clarify the role of anxiety in FOG as a causal factor, pathophysiological marker,
and manifestation of a common pathophysiological process versus a consequence of FOG itself. Clarifying the relationship
between anxiety and FOG could reveal anxiety reduction as a therapy for FOG.

1. Introduction
Parkinson’s disease (PD) is a neurological movement disorder characterized by four cardinal motor symptoms:
bradykinesia, rigidity, resting tremor, and postural instability [1]. It is a progressive disease with no cure and no
current disease-modifying therapies [2], and 60–80% of
dopamine-producing neurons in the substantia nigra pars
compacta degenerate over the course of the disease, leading
to substantial dopamine reduction in the dorsal striatum and
the aforementioned motor symptomatology [3]. These
motor symptoms progress in severity, eventually leading to
diminished ability to perform basic activities of daily living.
Pharmacological dopamine replacement therapy is used to
mitigate disabling PD motor sequelae, helping preserve
quality of life in the earlier stages of PD, but ultimately

produces disabling side eﬀects at higher doses which renders
this treatment undesirable in the later stages of PD [4]. PD is
further characterized by additional motor (i.e., gait freezing,
poor balance, and speech disturbances) and nonmotor (i.e.,
depression, anxiety, sleep disturbances, and fatigue)
symptoms [5].
Freezing of gait (FOG) is a particularly debilitating
motor symptom experienced by 50–80% of PD patients
[6, 7]. The third item on the Freezing of Gait (FOG)
Questionnaire reads as follows: “Do you feel that your feet
get glued to the ﬂoor while walking, making a turn, or trying
to initiate walking (i.e., freezing)?” [8]. This item functions as
a reliable screening tool for the presence of FOG. Intermittent in nature, experienced at later disease stages by
47% of PD patients at least bimonthly [6], episodes of FOG
increase susceptibility to falls, limit mobility, and reduce
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quality of life [9]. Much remains to be learned regarding the
pathogenesis of FOG. A small but growing body of research
indicates several variables likely contribute to this phenomenon, including PD motor phenotype, cognitive load,
emotional stimuli, and environmental factors [9].
Anxiety is a common, nonmotor symptom of PD, experienced by anywhere from 40% to 69% of Parkinson’s
patients [10, 32]. PD is often preceded by a prodromal state
of anxiety, with presence of anxiety positively associated
with intensity of motor impairments in PD [10]. Previous
studies have examined the interrelationship between anxiety
and motor symptomatology in PD, but the link between
anxiety and FOG in PD is not well characterized.
The aim of this literature review is to explore the degree
to which anxiety in PD is associated with eventual development and/or severity of FOG speciﬁcally. Exploring scientiﬁc consensus regarding the relation between anxiety
disorders and FOG in PD might reveal insights into the
pathophysiology of FOG and may suggest treatment options
for FOG not previously explored. As no current literature
review exists for this topic, this paper serves as a benchmark
in framing the current scientiﬁc understanding of anxiety’s
relationship to FOG, thereby facilitating future research
directions and treatment discoveries.

2. Methods
A systematic review of the PsycINFO, EMBASE, and
PubMed databases was performed to uncover studies
published before September 19, 2018, in which both anxiety
and FOG in PD were quantiﬁed and compared. To generate
an initial list of articles, the following search criteria were
applied to each database: (“Parkinson’s disease” OR
“Parkinson disease” OR “Parkinson’s) AND (“Anxiety” OR
“Generalized Anxiety Disorder” OR “Panic Disorder” OR
“Anxiety Disorder” OR “Panic Attack”) AND (“Freezing of
Gait” OR “Gait Freezing”).
A total of 138 articles were found from the initial database search: 32 on PsycINFO, 73 on EMBASE, and 33 on
PubMed. English-language, peer-reviewed studies investigating factors of anxiety and FOG in patients with a
conﬁrmed diagnosis of PD were included in this review.
Articles were excluded if they did not document and
compare anxiety and FOG as outcome measures, or if they
assessed festination/other gait disorders only and did not
clearly also provide measures of FOG. Additionally, reviews,
case report articles, and conference abstracts were excluded
from this analysis. See Table 1 for the list of inclusion and
exclusion criteria. The PRISMA Statement was used to guide
the systematic literature review. Figure 1 shows a ﬂow chart
of the study retrieval process.

3. Results
Our search revealed studies that were quite heterogeneous in
terms of demographics, anxiety measures, and FOG measures. The details and ﬁndings of each study are summarized
in Table 2.

Parkinson’s Disease
3.1. Demographics. Our analysis examines research from 11
countries with a combined total of 3,963 PD patients. All
studies included were conducted within the last 12 years,
with 20 of the 26 published between 2014 and 2018. This
recent inﬂux of research speaks to the increased awareness
of the relation between anxiety and FOG in PD. Nine
of the included studies used age-matched controls:
[24, 30, 31, 36, 37, 39–41, 43].
3.2. Measures of Parkinson’s Disease. Participants in all 26
studies had a conﬁrmed diagnosis of PD by a licensed
neurologist. The severity of PD was estimated with the
Uniﬁed Parkinson’s Disease Rating Scale-Motor Subscale
(UPDRS-III) for all patients in each of the studies included
in this review.
3.3. Measures of Anxiety
3.3.1. Hospital Anxiety and Depression Scale-Anxiety Component (HADS-A). Eleven studies employed the HADS-A to
quantify anxiety levels. The HADS is a 14-item self-assessment scale developed to detect depression and anxiety in
the hospital setting [11]. The anxiety component consists of 7
items with scores ranging from 0 to 3, with 0 being the lowest
anxiety level and 3 being the highest, for a range in score of
0–21.
3.3.2. Hamilton Anxiety Rating Scale (HAMA). Eight studies
used the HAMA as an outcome measure for anxiety. The
HAMA was designed as a clinician-based questionnaire but
is also used as a self-assessment scale. It consists of 14 items
related to symptoms and signs of anxiety graded on a 5-point
scale from 0 to 4 (with 0 being the least severe and 4 being the
most severe) with a range in score of 0–56 [12]. Items 10 and
11 of the Hamilton Depression Rating Scale are anxiety
related (HAMD-A), with both items scored on a 0–4 scale
for a total HAMD-A component score of 8 [13]. Patients in
the study of Zhang et al. [18] and Yao et al. [24] completed
the HAMD-A in addition to the HAMA.
3.3.3. Beck Anxiety Inventory (BAI). Four studies employed
the BAI as an outcome measure for anxiety. The BAI is a 21item 4-point self-report scale developed as a measure to
discriminate between depressive and anxiety symptoms [14].
Items are scored from 0 (least anxiety severity) to 3 (most
anxiety severity) with a score range from 0 to 63.
3.3.4. State and Trait Anxiety Inventory Scale (STAT-I).
One study implemented the STAT-I as an outcome measure
for anxiety. The STAT-I is a 40-item 4-point self-report scale
comprising 2 categories: state anxiety (20 items) and trait
anxiety (20 items). Items are scored as follows: 1 � almost
never, 2 � somewhat, 3 � moderately, and 4 � almost always,
with cumulative scores ranging from 20 to 80 [15].

Parkinson’s Disease
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Table 1: Inclusion and exclusion criteria.

Inclusion criteria

Exclusion criteria
(i) No exploration of anxiety and/or FOG as outcome
measures
(ii) Assessed festination or other gait disorders and
did not document measures assessing FOG
(iii) Review articles
(iv) Case reports
(v) Conference abstracts and nonpublished articles

(i) English language
(ii) Peer-reviewed
(iii) Participants with conﬁrmed diagnosis of PD
(iv) Compared both anxiety and FOG as primary
outcome measures
(v) Articles published up to September 19, 2018

PubMed (n = 33)
Initial database search
(n = 138)

EMBASE (n = 73)

Psycinfo (n = 32)

Number of duplicates
(n = 40)
Screened by title and
abstract (n = 46)
Research articles excluded after
applying exclusion criteria (n = 14)

Records after duplicate removal and
screening (n = 52)

(i) Assessed festination without
measures of FOG (n = 3)
(ii) Did not compare anxiety and
FOG as outcome measures
(n = 11)

Review articles (n = 9)
Unavailable online
(n = 3)

Research articles examined for
eligibility (n = 40)

Research articles included in literature
review (n = 26)

Figure 1

3.3.5. Parkinson’s Disease Questionnaire (PDQ-39). Only 1
study used a subset of the PDQ-39 as an outcome measure
for anxiety, speciﬁcally Items 21 and 9 which read as follows:
“During the last month have you felt anxious?” and “During
the last month have you felt frightened or worried about
falling over in public?” [16]. Scores on these items ranged
from 0 to 4 (0 � never, 1 � occasionally, 2 � sometimes,
3 � often, and 4 � always), with Item 21 used as a general
measure of anxiety and Item 9 used as a subjective measure
of anxiety during walking [42].
3.3.6. Parkinson’s Anxiety Scale (PAS). Only 1 study utilized
the PAS as an outcome measure for anxiety (n � 1). The PAS

is a 12-item observer- or self-reported scale that is composed
of 3 subscales: persisting anxiety (5 items), episodic anxiety
(4 items), and avoidance behaviour (3 items). The PAS is
scored on a scale of 0–4, with 0 representing “not or never”
and 4 representing “severe or almost always,” and the score
range is from 0 to 48 [29].
3.4. Measures of FOG. The studies included in the review are
particularly heterogeneous in their approach to assessing
FOG. Various combinations of the Freezing of Gait Questionnaire (FOG-Q), convincing subjective reports of the
FOG phenomenon and/or direct observation of FOG by an
experienced clinician/researcher, were used across studies

FOG measures

(i) A convincing subjective report of
FOG in addition to patient’s recognition
of FOG phenomenon when
demonstrated by an experienced
clinician.
OR
(ii) Answered yes to FOG-Q3OR
(iii) Reported by patients, their family
members, or caregivers when occurring
at home.
(a) FOG after 1 year � 40
(b) FOG after 2 years � 98
(c) FOG after 3 years � 128

(i) FOG-Q3 score used to diﬀerentiate
participants into 3 groups:
(ii) PDNF
(a) FOG-Q3: 0
(iii) PDmFOG
(a) FOG-Q3: 1
(iv) PDFOG
(a) FOG-Q3: 2–4

Anxiety measures
(i) Patients diagnosed by at least one
trained psychiatrist and who had
completed both the HAMA and HAMD
Anxiety subscale
(ii) At baseline, 51 PD patients were
diagnosed with anxiety, and 3 years later,
(a) 27 of these individuals developed
FOG
(b) 24 of these individuals did not
develop FOG
(iii) PD patients with FOG 3 years later
(n � 128)
(a) Overall HAMA: 11.35 ± 7.12
(b) HAMA-Somatic Anxiety:
4.81 ± 3.28
(c) HAMA-Psychic anxiety:
6.54 ± 3.96
(d) HAMD-Anxiety/Somatic:
2.79 ± 1.75
(iv) PD patients without FOG 3 years
later (n � 120)
(a) Overall HAMA: 10.23 ± 7.77
(b) HAMA-Somatic Anxiety:
4.44 ± 3.50
(c) HAMA-Psychic Anxiety:
5.79 ± 3.49
(d) HAMD-Anxiety/Somatic:
2.26 ± 1.43
(v) The paper mentions some patients
were on anxiolytics but does not report
numbers
(i) Anxiety subscale of HADS (HADSA) subtotalled and compared between
groups with scores ≥ 8 meeting criteria
for anxiety disorder
(ii) PDNF
(a) Mean HADS-A: 3.5 ± 0.22
(iii) PDmFOG
(a) Mean HADS-A: 4.7 ± 0.55
(iv) PDFOG
(a) Mean HADS-A: 5.8 ± 0.31
(v) To determine whether or not HADSA could predict FOG, PDmFOG group
combined with the PDFOG group and
HADS-A and HADS-D scores between
the two groups compared:
(a) PDNF (231 total): 14 patients with
anxiety and 10 patients with anxiety and
depression
(b) PDFOG combined (230 total): 26
patients with anxiety and 39 patients
with anxiety and depression
(vi) 129 patients in this study taking
anxiolytics and/or antidepressants
(a) 62/231 PDNF
(b) 13/50 PDmFOG
(c) 54/180 PDFOG

PD measures

(i) All participants diagnosed in
accordance with the UK Brain Bank
clinical criteria
(ii) UPDRS-III and H&Y stage used to
assess severity of PD motor symptoms
(iii) UPDRS-III score
(a) All 248 patients met the criteria
(b) Mean: 19.22 ± 2.61
(iv) H&Y stage:
(a) Stage 1 (n � 56)
(b) Stage 1.5 (n � 135)
(c) Stage 2 (n � 55)
(d) Stage 2.5 (n � 2)

(i) All participants had conﬁrmed
diagnosis of idiopathic PD by a trained
neurologist based on UK Brain Bank
clinical criteria
(ii) PDNF
(a) Mean UPDRS-III: 28.3 ± 1.1
(iii) PDmFOG
(a) Mean UPDRS-III: 33.5 ± 2.5
(iv) PDFOG
(a) Mean UPDRS-III: 41.55 ± 1.3
(v) Signiﬁcant group diﬀerences in
above scores observed in ANOVA
(p < 0.001), further covariate analysis
performed to factor UPDRS-III score
out of outcome measures analysis (in
addition to MMSE score and age)

(i) Chinese population
(ii) 248 PD patients
(a) 112 males; 136 females
(b) <65 years old (n � 78) mean age:
58.22 ± 5.43
(c) >65 years old (n � 170) mean age:
69.42 ± 3.41
(iii) Inclusion criteria: early-stage PD
patients, never experienced FOG prior
to study initiation, and never taken antiParkinson drugs
(iv) Exclusion criteria: presence of
atypical or secondary parkinsonism

(i) A 3-year prospective longitudinal
study where suspected risk factors for
FOG in patients with early-stage PD are
tabulated
(ii) Incidence of FOG assessed at one,
two, and three years following study
initiation to evaluate suspected risk
factors (including anxiety) associated
with future development of FOG
(iii) Participants recruited from the
Third People’s Hospital of Huzhou,
Zhejiang Province of China

(i) Australian population
(ii) 461 PD patients at the University of
Sydney-aﬃliated PD Research Clinic
recruited and split into 3 groups:
(iii) PD without FOG (PDNF) (n � 231)
(a) 150 males; 81 females
(b) Mean age: 67.8 ± 0.64
(i) To compare anxiety levels of PD
(c) Mean PD duration:
patients with FOG directly with PD
3.8 ± 0.56 years
patients without FOG, as well as how
(ii) PD with mild FOG (PDmFOG)
anxiety contributes to FOG
(ii) Participants recruited from a larger (n � 50)
(a) 34 males; 16 females
cohort of cases prospectively evaluated
(b) Mean age: 69.3 ± 1.09
between 2008 and 2015 and divided into
(c) Mean PD duration:
groups based on presence and severity of
6.3 ± 0.87 years
FOG and various clinical variables
(iii) PD with FOG (PDFOG) (n � 180)
tabulated and compared including
(a) 109 males; 71 females
anxiety
(b) Mean age: 69.2 ± 0.77
(c) Mean PD duration: 8.7 ± 0.6 years
(iv) Exclusion criteria: presence of
neurological disease other than PD,
psychiatric disorders other than aﬀective
disorder, and MMSE <24

Zhang et al. [18]

Martens et al. [19]

Table 2: Summary of studies included in literature review.
Demographic characteristics

Purpose and design

Authors

(i) An ANCOVA conducted across
groups demonstrated that, compared to
PDNF, PDFOG patients had
signiﬁcantly greater anxiety (p < 0.001);
PDmFOG was not signiﬁcantly diﬀerent
from PDFOG
(ii) Pearson’s correlations with stepwise
multiple regression analyses
demonstrated that, in all groups, severity
of anxiety symptoms was signiﬁcantly
correlated with FOG-Q3 scores
(p < 0.001)
(iii) In PDFOG combined compared
with PDNF, a signiﬁcant odds ratio of
3.40 (p < 0.001) when anxiety was
exposure outcome and FOG was the
variable
(ii) HADS-A score PPV of 28.26% (95%
CI 22.26%–34.35%) for identifying
patients with FOG
(iii) HADS-A score NPV of 89.61% (95%
CI: 84.94%–93.23%) for identifying
patients without FOG

Following age-adjusted ANCOVA:
(i) No signiﬁcant association with
HAMA scores at baseline and FOG
3 years later
(ii) Signiﬁcantly higher HAMD anxiety
scores in FOG compared with non-FOG
patients 3 years later (p � 0.002)
Following binary logistic regression
analysis:
(i) Baseline HAMD Anxiety signiﬁcantly
associated with future development of
FOG 2 years later (p � 0.033) but not
1 year later (p � 0.217)

Notable results
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Parkinson’s Disease

(i) Australian population
(ii) 203 PD patients
(a) 139 males; 64 females
(b) Mean age: 66.77 ± 8.9
(c) Mean PD duration:
61.30 ± 61.3 months
(iii) Excluded if MMSE <24

(i) Canadian population
(ii) 31 PD patients divided into freezers
and nonfreezers:
(iii) 14 freezers:
(a) 11 males; 3 females
(i) Previous diagnosis of idiopathic PD
(b) Mean age: 71 ± 7.8
by a neurologist
(iv) 17 nonfreezers:
(ii) Mean UPDRS-III score:
(a) 14 males; 3 females
(a) Freezers: 34 ± 10.1
(b) Mean age: 66 ± 8.7
(b) Nonfreezers: 20 ± 10.4
Exclusion criteria: unable to walk 10 m
unassisted, severe vertigo, motion
sickness, severe kyphosis, other
neurological disorders, severe head
tremor, or dyskinesias

(i) To induce anxiety via virtual reality
and measure presence/severity of FOG
in a controlled experimental setting
(ii) 10 randomized walking trials across
a 6-metre long plank positioned between
two platforms in one of the two diﬀerent
virtual 3-D environments: a low
condition wherein the plank was
positioned on the ﬂoor of the virtual
environment, and a high condition
wherein the plank was positioned over a
pit 8 metres in depth of the virtual
environment
(iii) Patients recruited through a Wilfrid
Laurier University aﬃliated Research
and Rehabilitation Centre in Waterloo,
Canada

(i) Chinese population
(ii) 474 PD patients
(iii) 221 with FOG
(a) 117 males; 104 females
(b) 108 ≤ 65 years old
(c) 113 ≥ 65 years old
(i) To explore the prevalence and clinical
(d) Mean age: 64.36 ± 10.16
correlates of FOG
(e) Mean PD duration:
(ii) A cross-sectional observational
5.97 ± 4.24 years
study and participants were recruited
(iv) 252 without FOG
from Department of Neurology, West
(a) 140 males; 113 females
China Hospital of Sichuan University
(b) 155 ≤ 65 years old
between May 2011 and April 2014
(c) 98 ≥ 65 years old
(d) Mean age: 60.11 ± 10.50
(e) Mean PD duration:
3.73 ± 3.55 years
(v) Atypical or secondary parkinsonism
excluded

Walton et al. [20]

Ehgoetz Martens
et al. [32]

Ou et al. [21]

(i) Patients previously diagnosed with
UK Brain Bank criteria for PD
(ii) H&Y stage and UPDRS-III used to
assess severity
(iii) Freezer H&Y stage
(a) Stage 1–2.5: 115
(b) Stage 3: 74
(c) Stage 4-5: 32
(d) Median: 2.5 (1.0)
(iv) Nonfreezer H&Y stage
(a) Stage 1–2.5: 228
(b) Stage 3: 20
(c) Stage 4-5: 3
(d) Median: 2.0 (0.5)
(v) Mean UPDRS-III score:
(a) Freezers: 35.90 ± 14.48
(b) Nonfreezers: 24.10 ± 10.45

(i) HAMA scores quantiﬁed for freezers
vs. nonfreezers:
(a) Mean HAMA freezers: 9.64 ± 7.50
(b) Mean HAMA nonfreezers:
6.21 ± 5.92

(i) State and Trait Anxiety Inventory
Scale assessed baseline levels of anxiety
prior to completing experiment:
(ii) Freezers
(a) Average STAI-Trait: 33 ± 6.9
(b) Average STAI-State: 34 ± 8.7
(iii) Nonfreezers
(a) Average STAI-Trait: 32 ± 6.6
(b) Average STAI-State: 30 ± 5.9
(iii) Participants additionally completed
a 9-point self-assessment manikin scale
after each walking trial to quantify
anxiety experienced during the
experiment

(i) All participants had conﬁrmed
diagnosis of idiopathic PD based on
United Kingdom Brain Bank clinical
criteria by a trained neurologist
(ii) Mean UPDRS-III score: 27.60 ± 15.1
HADS-A score quantiﬁed:
(iii) H&Y stage
(a) Mean: 3.95 ± 3.4
(a) Stage 1: 39 (19.21%)
(b) Stage 1.5: 7 (3.45%)
(c) Stage 2: 98 (48.28%)
(d) Stage 2.5: 39 (19.21%)
(e) Stage 3: 20 (9.85%)

Anxiety measures

Table 2: Continued.

(i) To examine the impact of FOG on the
Health-Related Quality of Life scale in
PD patients
(ii) Additionally, other factors that are
known to impact patient well-being
were assessed (including anxiety)
(iii) Data collected from baseline
assessment of a group of PD patients
from December 2008 and November
2013 patients at the University of
Sydney-aﬃliated PD Research Clinic

PD measures

Demographic characteristics

Purpose and design

Authors

(i) Pearson’s bivariate correlation
indicated HADS-A score signiﬁcantly
associated with severity of FOG
(p < 0.01)

Notable results

(i) Freezing episodes observed by the
neurologist during visit or reported by
patient/family/caregiver if happened at
home
(ii) FOG-Q3 is used to assess

(i) 46.62 % prevalence of FOG in this
population of PD patients
(ii) ANCOVA adjusted for age, disease
duration, and H&Y stage total HAMA
scores signiﬁcantly higher in freezers
than nonfreezers (p < 0.001)
(iii) Binary logistic regression model
indicated no signiﬁcant correlation
between HAMA anxiety score and FOG
(p � 0.333)

(i) Freezers spent a signiﬁcantly greater
portion of time frozen in the high
condition compared to the low
condition (F(1,13) � 11.35, p < 0.005)
(ii) Freezers exhibited signiﬁcantly
higher numbers of freezing episodes in
the high condition relative to the low
(i) Previous history of FOG and selfcondition (F(1,13) � 8.29, p < 0.013), but
reported FOG using the UPDRS-II and
no signiﬁcant diﬀerences in duration of
FOG conﬁrmed by movement disorder
freezing episodes (F(1,13) � 2.48,
specialist prior to participation in study
p � 0.14)
diﬀerentiated freezers from nonfreezers
(iii) Freezers self-reported signiﬁcantly
(ii) Freezers vs. nonfreezers
higher levels of anxiety during the
(a) Low condition: % of each trial
experiment than nonfreezers (F(1,29) �
frozen � 11.03 ± 23 seconds
16.96, p � 0.0003), with both groups
(b) High condition:
reporting signiﬁcantly higher levels of
% of each trail frozen � 23.1 ± 28.7
anxiety in the high condition compared
to the low condition (F(1,29) � 29.83,
p < 0.001)
(iv) No signiﬁcant diﬀerences between
freezers and nonfreezers in terms of
STAI-Trait (p � 0.37) and STAI-state
scores (p � 0.20)

(i) FOG-Q3 score used to identify
patients that had experienced FOG:
(a) 86 patients ≥1 (43% FOG)
(ii) Full 6-Item FOG-Q used to assess
severity of FOG:
(b) Mean score: 5.34 ± 5.7

FOG measures

Parkinson’s Disease
5

(i) Each PD patient examined by the
neurologist with standardized/
structured interview

(i) Patients with a previous diagnosis of
PD recruited from specialist movement
disorder and care of the elderly clinics
(ii) Freezer H&Y stage
(a) Stage 1–2.5: 115
(b) Stage 3: 74
(c) Stage 4-5: 32
(d) Median: 2.5 (1.0)
(iii) Nonfreezer H&Y stage
(a) Stage 1–2.5: 228
(b) Stage 3: 20
(c) Stage 4-5: 3
(d) Median: 2.0 (0.5)
(iv) Mean UPDRS-III score:
(a) Freezers: 35.90 ± 14.48
(b) Nonfreezers: 24.10 ± 10.4

(i) Patients previously diagnosed with
PD

(i) UK population
(ii) 513 PD patients
(iii) Phenomenological data relating to
depression and anxiety collected by
trained staﬀ using the Geriatric Mental
State semi-structured interview and
sorted into 4 groups:
(a) Anxious-depressed (8.6%)
(i) To identify associations between
(b) Depressed (9.0%)
phenotypic variants of motor and mood
(c) Anxious (22%)
subtypes of PD
(d) Low-level psychiatric
(ii) Cross-sectional study
(iii) Participants were recruited over a symptomatology (60.4%)
period of 12 months from specialist PD Inclusion criteria: able to provide
or movement disorder outpatient clinics informed consent and resided within
as part of the PROMS-PD longitudinal 2 hours travel time of a study research
centre
study
Exclusion criteria: the presence of
communication diﬃculty or sensory
deﬁcits that interfered with assessment.
Cognitive impairment and severe
psychiatric disorders only met exclusion
criteria if they were severe enough to
aﬀect capacity to consent

(i) US population
(ii) 109 patients:
(a) 72 males; 37 females
(i) To study the association between
(b) Mean age: 69.0 ± 11.4
anxiety, depression, and panic with FOG
(c) PD duration: 7.6 ± 5.7
in Parkinson’s patients
(iii) Patient’s completed the Activities of
Daily Living section of the UPDRS
which contains a question about
freezing

Perez-Loret et al.
[34]

Burn et al. [22]

Lieberman [23]

PD measures

(i) French population
(i) To determine prevalence of FOG and
(ii) 672 patients:
assess its relationship with quality of life
(a) 381 males; 291 females
and other clinical factors (including
(b) Age ≥ 68: 341
anxiety)
(c) PD duration ≥ 5 years: 341
(ii) Cross-sectional study
(iii) Exclusion criteria: patient’s
(iii) Patients included prospectively as
<18 years old, MMSE <24, undergoing
outpatients of public or private
deep brain stimulation, and having
practicing neurologists in 32 centres
serious disease aﬀecting life expectancy
from 4 diﬀerent regions of France
in the short term

Demographic characteristics

Purpose and design

Authors

(i) FOG identiﬁed by scores ≥1 on Item
14 of UPDRS-II
(ii) Nonfreezers: 415
(iii) Freezers: 257

(i) HAMA scores quantiﬁed with score
ranges of 18–54 meeting criteria for
anxiety
(a) 18/29 with FOG (62%)
(b) 14/80 without FOG (18%)
(ii) DSM-IV criteria for panic attacks
used to identify presence of panic attacks
(a) 14/29 with FOG (48%)
(b) 6/80 without FOG (80%)

(i) The mean total HADS-A scores in
freezers was signiﬁcantly higher than in
nonfreezers (p < 0.001), with a
signiﬁcantly higher proportion of
freezers meeting the HADS-A ≥ 11
criteria for anxiety than nonfreezers
(p < 0.017)
(ii) Presence of FOG did not predict
membership in the anxious-depressed,
depressed, or anxious mood subtypes

(i) 38.2% FOG point prevalence
reﬂecting a mixed population of patients
with early and advanced disease who
were still ambulatory, with or without
motor ﬂuctuations
(ii) No signiﬁcant diﬀerences between
HADS-A anxiety in freezers vs
nonfreezers

Notable results

(i) Those that answered yes to the initial
(i) FOG was signiﬁcantly associated with
freezing question (item 14 of UPDRS-II)
anxiety (p < 0.002) and panic attacks
further questioned and evaluated using 6
(p < 0.0001)
Item FOG-Q to calculate FOG severity

(i) Anxiety subscale of HADS (HADSA) subtotalled with scores ≥ 11 meeting
criteria for signiﬁcant anxiety symptoms
(i) FOG identiﬁed by scores >1 on Item
(22.0%)
14 of UPDRS-II
(ii) Number of PD patients with
(a) FOG present: 75 patients (14.62%)
HADS ≥ 11
(b) FOG not present: 438 patients
(a) Freezers: 25 (33%)
(85.38%)
(b) Nonfreezers: 87 (20%)
(iii) Mean total HADS-A Score
(a) Freezers: 8.8 ± 4.6
(b) Nonfreezers: 6.9 ± 4.4

FOG measures

Anxiety measures
(i) Anxiety subscale of HADS (HADSA) subtotalled, with a number of PD
patients with scores ≥ 7 totalled and
compared between freezers and
nonfreezers
(ii) Freezers
(a) Number of PD patients with
HADS-A ≥ 7: 136
(iii) Nonfreezers
(a) Number of PD patients with
HADS-A ≥7: 194

Table 2: Continued.
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(i) All participants had conﬁrmed
diagnosis of idiopathic PD based on
United Kingdom Brain Bank clinical
criteria by a trained neurologist
(ii) Freezers
(a) Mean H&Y stage: 2.00 ± 0.42
(b) Mean UPDRS-III: 25.66 ± 14.11
(iii) Nonfreezers
(a) Mean H&Y stage: 1.85 ± 0.44
(b) Mean UPDRS-III: 20.85 ± 10.70

(i) After diagnosis by the neurologist, a
total of 186 PD patients were selected for
the study
(ii) FOG PD patients (n � 104)
(a) UPDRS-I: 4.53 ± 1.24
(b) UPDRS-II: 10.64 ± 3.42
(c) UPDRS-III: 13.71 ± 4.16
(d) H&Y rating: 2.01 ± 0.26
(e) Levodopa therapy, n: 62 (59.62%)
(f ) Dopamine agonist therapy, n: 42
(40.38%)
(iii) Non-FOG PD patients (n � 82)
(a) UPDRS-I: 3.32 ± 1.54
(b) UPDRS-II: 6.85 ± 3.32
(c) UPDRS-III: 9.27 ± 3.81
(d) H&Y rating: 1.92 ± 0.31
(e) Levodopa therapy, n: 51 (62.2%)
(f ) Dopamine agonist therapy, n: 31
(37.8%)

(i) Chinese population
(ii) 186 patients with PD
(iii) FOG PD patients (n � 104)
(a) 55 males; 49 females
(b) Mean age: 65.72 ± 7.34
(c) Mean PD duration:
9.52 ± 1.54 years
(d) Years of education: 13.51 ± 4.24
(iv) Non-FOG PD patients (n � 82)
(a) 44 males; 32 females
(b) Mean age: 66.35 ± 8.67
(i) Exploring whether cognitive
(c) Mean PD duration:
impairment is correlated with
9.16 ± 1.27 years
occurrence of FOG in PD
(d) Years of education: 12.82 ± 3.67
neuropsychological assessments utilized
(v) 125 health controls
to evaluate cognitive functioning:
(a) 66 males; 59 females
SCOPA-COG, UPDRS, MMSE, HAMA,
(b) Mean age: 65.91 ± 6.86
and HAMD.
(c) Years of education: 13.32 ± 2.93
(ii) Data collected from PD patients
(vi) Inclusion criteria: disease duration
diagnosed and treated in YangPu,
<10 years, MMSE ≥24, H&Y stage ≤2.5,
Nanjing Drum Tower and Huashan
signs of stabilization with
hospitals
antiparkinsonism treatment prior to
(iii) Case-control study
study
(vii) Exclusion criteria: signiﬁcant
comorbidities exhibit signs of
depression/anxiety, patients diagnosed
with cardiovascular and/or
cerebrovascular disease, anticholinergic
treatments, orthopaedic or additional
neurological disorders
(PD and control group subjects matched
for gender, age, year of education, and
course of disease)

Hall et al. [35]

Yao et al. [24]

PD measures

(i) Australian population
(ii) 91 PD patients
(iii) Freezers (n � 38)
(a) 27 males; 11 females
(b) Mean age: 65.20 ± 9.00
(c) Mean PD duration:
1.91 ± 1.40 years
(i) Evaluate domains of motor,
(iv) Nonfreezers (n � 53)
cognitive, aﬀective, autonomic, and
(a) 35 males; 18 females
REM sleep behaviour disorder in early(b) Mean age: 64.58 ± 8.63
stage PD and their respective
(c) Mean PD duration:
associations with FOG
1.69 ± 1.26 years
(ii) Data collected from baseline
(v) Included if a H&Y stage <3 and a
assessment of a group of PD patients
disease duration of 5 years or less
from December 2008 and November
(vi) Excluded on the presence of other
2013 at the University of Sydneyneurological diseases, conditions that
aﬃliated PD Research Clinic
would impair gait, or presence of
dementia as rated by Movement
Disorder Task Force criteria
(vii) No signiﬁcant diﬀerences in age,
years of education, and disease duration
between freezers and nonfreezers

Demographic characteristics

Purpose and design

Authors

(i) Mean HAMA scores (including
somatic/psychic anxiety subdomains)
and the HAMD-anxiety/somatic
subdomain were quantiﬁed and
compared between FOG and non-FOG
PD patients
(ii) FOG PD patients:
(a) Overall HAMA: 11.14 ± 3.71
(b) HAMA-Somatic Anxiety:
5.20 ± 2.51
(c) HAMA-Psychic Anxiety:
7.14 ± 3.12
(d) HAMD-Anxiety/Somatic:
3.12 ± 1.12
(iii) Non-FOG PD patients:
(a) HAMA: 9.96 ± 3.21
(b) HAMA-Somatic Anxiety:
4.93 ± 2.60
(c) HAMA-Psychic Anxiety:
6.23 ± 3.43
(d) HAMD-anxiety/somatic:
2.67 ± 1.03
(iv) HAMD-Anxiety scale score
compared with severity of FOG within
FOG patients
(v) The paper does not document
incidence of anxiolytic treatment

(i) HADS-A scores quantiﬁed for
freezers vs. nonfreezers:
(a) Mean HADS-A freezers:
4.92 ± 4.58
(b) Mean HADS-A nonfreezers:
3.42 ± 2.49

Anxiety measures

Table 2: Continued.

(i) Despite higher mean scores on the
HADS-A scale, no signiﬁcant diﬀerences
were noted between anxiety scores of
freezers compared with nonfreezers
(p � 0.800)

Notable results

(i) Two-tailed t-test comparing HAMA
scores between FOG and non-FOG PD
patients showed higher mean scores for
the FOG group but no statistically
signiﬁcant diﬀerences between groups.
(i) FOG identiﬁed by 2/3 criteria used by
(ii) Higher mean scores and signiﬁcant
Snijders et al. (2011):
diﬀerences between the HAMD(a) Convincing subjective reports of
Anxiety/Somatic scale were observed
FOG
between groups: overall HAMA
(b) Patient’s subjective recognition of
(p � 0.016), HAMA-Somatic Anxiety
FOG when demonstrated by an
(p � 0.47), HAMA-Psychic Anxiety
experienced clinician
(p � 0.06), and HAMD-Anxiety
(c) Scores ≥1 on nFOG-Q
(p � 0.005)
(ii) nFOG-Q used to assess severity of
(iii) Spearman’s rho correlation between
FOG
HAMD-Anxiety and FOG
questionnaire demonstrated severity of
FOG positively correlated with anxiety
within the FOG group:
(a) r � 0.79 (p < 0.0001)

(i) FOG-Q3 used to separate freezers
from nonfreezers
(a) ≥1: 38 freezers (41.76%)
(b) 0: 53 nonfreezers (58.24%)

FOG measures
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PD measures

(i) A movement disorders neurologist
enrolled all participants during routine
clinic visits. All enrolled patients met
UK Brain Bank criteria for PD.

Demographic characteristics
(i) Canadian population
(ii) 14 participants completed entire
study protocol (out of 18 total); PD
patients separated into 3 groups upon
completion of rasagiline therapy and
subsequent analysis: improved,
worsened, and no change
(iii) Improved (n � 6)
(a) 5 males; 1 females
(b) Mean age: 69.7 ± 3.88
(c) Mean PD duration: 9.8 ± 3.13 years
(d) Mean FOG duration:
5.2 ± 2.64 years
(iv) Worsened (n � 5)
(a) 4 males; 1 females
(b) Mean age: 67.8 ± 7.40
(c) Mean PD duration:
12.0 ± 5.34 years
(d) Mean FOG duration:
4.0 ± 2.00 years
(ii) No change (n � 3)
(a) 3 males, 0 females
(b) Mean age: 67.8 ± 7.40
(c) Mean PD duration:
15.67 ± 7.02 years
(d) Mean FOG duration:
5.0 ± 2.00 years
(v) No signiﬁcant diﬀerences among
groups for any of the demographic or
baseline variables between the 3 groups
(p values ≥0.10)
(vi) Inclusion criteria: H&Y scores
between 2 and 4, experienced intractable
FOG even with optimal dopaminergic
treatment, on stable clinically optimated
medications for 3 months prior and
were clinically determined to require
adjunct therapy with rasagiline
(vii) Exclusion criteria: history of
neurological procedures, other
neurological disorders, untreated
clinical depression, diagnosed GAD,
dementia, and use of a gait aid

Purpose and design

(i) A pilot study wherein optimally
medicated PD patients with intractable
FOG were treated with a 90-day course
of 1 mg rasagiline, with FOG and
cognitive/motor measures assessed prior
to and following treatment
(ii) UPDRS motor section (Items
18–31), MoCA, BAI, BDI, FOG-Q, 6
scripted gait tasks, and free walking task
administered pre- and posttreatment.
Gait tasks were video-recorded with
subsequent analysis by two independent
examiners
(iii) Prospective, experimental, pre-/
posttreatment design, uncontrolled
design
(iv) Participants recruited from a
movement disorders clinic in London,
on using the convenience-sampling
method

Authors

Rahimi et al. [25]

(i) BAI scale used to assess anxiety
(ii) Improved
(a) Mean pretreatment BAI score:
13.0 ± 7.43
(b) Mean posttreatment BAI score:
15.7 ± 8.69,
(ii) Worsened (n � 5)
(a) Mean pretreatment BAI score:
18.2 ± 9.15
(b) Mean posttreatment BAI score:
16.2 ± 10.59
(iii) No change (n � 3)
(a) Mean pretreatment BAI score:
12.7 ± 9.24
(b) Mean posttreatment BAI score:
13.7 ± 15.18

Anxiety measures

Table 2: Continued.

(i) FOG diagnosed by movement
disorders neurologist through gait
analysis in clinic, patient report
corroborated by a family member, and
clinical history, UPDRS scores, and
FOG-Q scores administered at the ﬁrst
visit

FOG measures

(i) No signiﬁcant diﬀerences in pre-/
posttreatment BAI scores (t(13) � 0.26,
p � 0.80), or overall count and duration
of FOG episodes (F(1,13) � 0.96,
p � 0.34; F(1,13) � 1.00, p � 0.34,
respectively)
(ii) Higher BAI anxiety scores predicted
FOG worsening following rasagiline
therapy (p < 0.0024)
(iii) Final predictive model explained
99% of the variance between the
improved and worsened groups as a
function of treatment with rasagiline

Notable results
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PD measures

(i) A diagnosis of idiopathic PD made by
a specialist experienced in movement
disorders based on UK Brain Bank
Criteria.
(ii) Median UPDRS-III score:
(a) Freezers: 35.0 (33.0–38.3)
(b) Nonfreezers: 36.0 (31.5–37.3)
(c) Controls: 0 (0–2.0)
(iii) Median H&Y stage:
(a) Freezers: 2.5 (2.5–3.0)
(b) Nonfreezers: 2.5 (2.0–3.0)
(data are shown as median (25th–75th
quartile)

(i) A diagnosis of idiopathic PD made by
a specialist experienced in movement
disorders based on UK Brain Bank
Criteria.
(ii) Mean baseline UPDRS-III scores:
(a) Continuing freezers: 48.64 ± 20.68
(b) Transitional freezers: 35.14 ± 17.07
(c) Nonfreezers: 24.51 ± 13.62
(iii) Mean follow-up UPDRS-III scores:
(a) Continuing freezers: 49.81 ± 21.06
(b) Transitional freezers: 38.42 ± 15.33
(c) Nonfreezers: 25.51 ± 14.40

Demographic characteristics
(i) South Korean population
(ii) 47 patients with PD
(iii) FOG PD patients (n � 25)
(a) 13 males; 12 females
(b) Median age: 64.0 (58.5–69.5)
(c) Median PD duration: 10.0
(8.0–12.0)
(d) Median years of education: 12.0
(12.0–16.0)
(iv) Non-FOG PD patients (n � 22)
(a) 13 males; 9 females
(b) Median age: 64.5 (61.0–67.8)
(c) Median PD duration: 9.0
(7.8–10.3)
(d) Median years of education: 12.0
(9.0–16.0)
(v) 26 healthy controls
(a) 13M, 13F
(b) Median age: 64.0 (62.0–66.0)
(c) Median years of education: 12.0
(12.0–16.0)
(vi) No signiﬁcant diﬀerences between
gender, age, and years of education
between the 3 groups
(vii) No signiﬁcant diﬀerent between
years of PD duration between FOG PD
patients and non-FOG PD patients
Exclusion criteria: unable to stand safely
unaided, history of falls in the last
12 months, dementia, visual
disturbances, clinical signs of disorders
aﬀecting proprioception,
musculoskeletal problems, orthostatic
hypotension, neurosurgical
interventions, history, or clinical signs of
vestibular disease
(data are shown as median (25th–75th
quartile))

Purpose and design

(i) Case control cross-sectional design
(ii) Examined postural sensory deﬁcits
linked to FOG severity through a
computerized dynamic posturography
system
(iii) Participants evaluated with a
sensory organization test and several
clinical measures (including anxiety)
(iv) Participants recruited through
Samsung Medical Centre
(v) Clinical, neurological exams, and
posturography were performed during
the morning oﬀ-medication, at least
12 hours after holding Parkinson’s
medications

(i) Australian population
(ii) 221 PD patients
(iii) Continuing freezer (n � 92)
(a) 56 males; 36 females
(b) Mean age: 70.24 ± 10.85
(c) Mean PD duration:
(i) Prospective longitudinal study design
9.66 ± 7.50 years
(ii) PD patients were separated into 3
groups based on their responses to FOG- (iv) Transitional freezer (n � 41)
(a) 26 males; 15 females
Q3 at baseline and a follow-up point
(b) Mean age: 70.75 ± 9.39
6–24 months later, with measures of
(c) Mean PD duration:
anxiety and FOG severity taken at both
5.97 ± 4.14 years
of these time points
(v) Nonfreezers (n � 88)
(iii) Participants recruited from
(a) 52 males; 36 females
University of Sydney’s PD Research
(b) Mean age: 65.37 ± 9.84
Clinic at the Brain and Mind Centre
(c) Mean PD duration:
from 2008 to 2016
3.16 ± 4.32 years
(vi) Signiﬁcant group eﬀects for age
(p � 0.002) and disease duration
(p < 0.001) found and therefore entered
as covariates in subsequent analysis

Authors

Huh et al. [36]

Ehgoetz Martens
et al. [28]

(i) HADS-A used to assess anxiety
(ii) Mean baseline HADS-A scores:
(a) Continuing freezers: 2.94 ± 3.89
(b) Transitional freezers: 3.65 ± 3.08
(c) Nonfreezers: 1.18 ± 2.31
(iii) Mean follow-up HADS-A scores:
(a) Continuing freezers: 5.38 ± 4.19
(b) Transitional freezers: 5.18 ± 4.68
(c) Nonfreezers: 3.62 ± 2.93

(i) BAI used to assess anxiety
(ii) FOG PD patients:
(a) Median: 7.0 (3.0–14.0)
(iii) Non-FOG PD patients:
(a) Median: 5.0 (3.0–12.3)
(iv) Controls:
(a) Median: 1.0 (0–2.0)
(data are shown as median (25th–75th
quartile)

Anxiety measures

Table 2: Continued.

(i) FOG-Q3 used to assign participants
to groups based on scores, FOG-Q total
used to assess severity (with Item 3
removed)
(ii) Mean FOG-Q total scores:
(a) Continuing freezers: 10.23 ± 4.19
(b) Transitional freezers: 2.68 ± 1.74
(c) Nonfreezers: 1.41 ± 1.37
(iii) Mean follow-up FOG-Q total
scores:
(a) Continuing freezers: 10.79 ± 4.02
(b) Transitional freezers: 6.17 ± 2.39
(c) Nonfreezers: 1.68 ± 1.60

(i) nFOG-Q used to assign participants
to the FOG group based on item 1 of the
questionnaire (if they had experienced
FOG during the past month), and if ≥ 1,
FOG episodes were elicited and detected
by 2 movement specialists using a 2minute tight and rapid turning-in-place
protocol
(ii) FOG PD patients:
(a) Median nFOG-Q: 12.0 (10.5–18.5)
(iii) Non-FOG PD patients:
(a) Median: 0
(data are shown as median (25th–75th
quartile)

FOG measures

(i) HADS-A scores increased
signiﬁcantly from baseline to follow-up
across all 3 groups, and both continuing
and transitional freezers had
signiﬁcantly greater mean HADS-A
scores than nonfreezers at baseline and
follow-up
(ii) Correlational analysis revealed
HADS-A scores were signiﬁcantly
associated with FOG-Q total scores
(0.206, p < 0.01)—predictive model
constructed with HADS-A and FOG-Q
total score as variables with the overall
predictive success of 82.1%

(i) FOG patients and non-FOG patients
had signiﬁcantly higher BAI scores than
the control group (p < 0.001) with no
signiﬁcant diﬀerence between groups
(p � 0.980)

Notable results
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(i) A diagnosis of idiopathic PD made by
a trained neurologist based on UK Brain
Bank Criteria
(ii) MRI+
(a) Mean UPDRS-III: 34.15 ± 12.19
(b) MRI−
(c) Mean UPDRS-III: 33.62 ± 15.84

(i) Australian population
(ii) 41 PD patients with FOG, 5 freezing
episodes were required in the MRI
scanner for eﬀective modelling of
freezing events: 20 met this criteria
(MRI + group), while 21 did not (MRI
(i) An experimental task-based fMRI
group)
study
(iii) MRI+
(ii) PD patients with FOG completed
(a) 17M, 3F
virtual reality gait paradigm while in 3T
(b) Mean age: 66.45 ± 5.34
MRI scanner
(iii) MRI−
(iii) Baseline assessment data, including
(a) 15 males; 16 females
anxiety outcome measures, performed
(b) Mean age: 68.75 ± 7.26
on all participants
(iv) Inclusion criteria: FOG-Q3 ≥ 1,
(vi) Gait observed during the virtual
clinically evident FOG conﬁrmed by a
reality task (foot tapping) was compared
neurologist, ability to complete virtual
between freezing episodes and normal
reality task in MRI scanner after a
foot-tapping using fMRI
minimum of 12 hours following intake
(v) Participants recruited from
of dopaminergic medication (oﬀ state)
University of Sydney’s Brain and Mind
(v) Exclusion criteria: neurological
Centre
comorbidities and presence of
pathological lesions/abnormalities on
structural imaging
(vi) Notably MRI+ and − groups were
matched in age, symptom severity,
FOG-Q3, and anxiety

Ou et al. [27]

Ehgoetz Martens
et al. [26] (fMRI
study)

(i) HADS-A used to assess anxiety
(ii) MRI+
(a) Mean HADS-A: 6.3 ± 3.25
(iii) MRI−
(a) Mean HADS-A: 5.29 ± 3.98

(i) HAMA used to assess anxiety
(ii) Mean baseline HAMA scores:
(a) Freezers: 10.3 ± 6.8
(b) Nonfreezers: 7.2 ± 5.8
(iii) Mean follow-up HAMA scores:
(a) Freezers: 11.0 ± 6.9
(b) Nonfreezers: 7.7 ± 6.0
(iv) Average change in HAMA score
(a) Freezers: −0.2 ± 1.9
(b) Nonfreezers: −0.2 ± 1.7

Anxiety measures

Table 2: Continued.

(i) A diagnosis of idiopathic PD made by
a trained neurologist based on UK Brain
Bank Criteria
(ii) Mean baseline UPDRS-III scores:
(a) Freezers: 32.9 ± 12.8
(b) Nonfreezers: 21.4 ± 10.5
(iii) Mean follow-up UPDRS-III scores:
(a) Freezers: 44.3 ± 14.8
(b) Nonfreezers: 29.8 ± 11.2
(iv) Average change in UPDRS-III score
(a) Freezers: 3.7 ± 3.4
(b) Nonfreezers: 3.2 ± 3.0
(v) Mean baseline H&Y stages:
(a) Freezers: 2.4 ± 0.6
(b) Nonfreezers: 1.5 ± 0.6
(vi) Mean follow-up H&Y stages:
(a) Freezers: 2.9 ± 0.8
(b) Nonfreezers: 2.2 ± 0.5

PD measures

(i) Chinese population
(ii) 225 PD patients
(iii) 85 developed FOG after 3 years
(a) 44 males; 41 females
(b) Mean age: 62.5 ± 11.1
(c) Mean PD duration: 6.8 ± 3.3 years
(iv) 140 did not develop FOG after
(i) Prospective longitudinal study design 3 years
(a) 85 males; 55 females
(ii) PD patients were assessed at baseline
(b) Mean age: 58.1 ± 12.6
and at follow-up 2.5–3 years later to
(c) Mean PD duration: 4.5 ± 2.4 years
investigate potential clinical predictors
(v) Inclusion criteria: between H&Y
of FOG, which included anxiety
stages I-III, no prior FOG
(iii) Participants
recruited from West China Hospital of (vi) Exclusion criteria: atypical or
secondary Parkinsonism, unstable
Sichuan’s Department of Neurology
disease, participants who declined
between March 2012 and May 2013
follow-up
(vii) Freezers signiﬁcantly older
(p � 0.009) and had signiﬁcantly longer
PD duration (p < 0.001) than
nonfreezers on average and further
analysis done with ANCOVA adjusted
for age and disease duration

Demographic characteristics

Purpose and design

Authors

(i) FOG-Q3 ≥ 1 an inclusion criteria for
the study used to identify PD patients
with FOG in this study, which was
additionally conﬁrmed by a neurologist
(ii) Objective measures of FOG collected
through virtual gait paradigm
(iii) MRI +
(a) Mean step time variability:
24.99 ± 7.04 s
(b) Modal foot step latency:
0.38 ± 0.17 s
(c) Overall time spent frozen:
0.14 ± 0.08%
(iv) MRI−
(a) Mean step time variability:
21.27 ± 8.32 s
(b) Modal foot step latency:
0.64 ± 0.29 s
(c) Overall time spent frozen:
0.07 ± 0.14%
(v) HADS-total one of three variables
used to calculate the Freezing
Component Index which was compared
to the freezing network signature
collected via fMRI

(i) FOG-Q3 ≥ 1 used to separate freezers
from nonfreezers
(ii) Freezing episodes observed by the
neurologist during visit or reported by
patient/family/caregiver if happened at
home

FOG measures

(i) Higher HADS-A scores associated
with increased coupling between limbic
network and ventral striatum +
cognitive control network during gait
freezing compared to normal foot
tapping

(i) Higher mean HAMA scores in
freezers than nonfreezers at both
baseline and follow-up (p < 0.001)
(ii) Annual change in HAMA did not
diﬀer signiﬁcantly between groups
(p � 0.780)
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Ehgoetz Martens
et al. [28]

(i) PD patients with conﬁrmed FOG
participated in the study
(ii) Anxious subgroup
(a) Mean H&Y stage: 2.8 ± 0.7
(b) Mean UPDRS-III ON: 38.7 ± 10.1
(c) Mean UPDRS-III OFF: 44.9 ± 9.6
(iii) Asymmetric-motor subgroup
(a) Mean H&Y stage: 2.5 ± 0.9
(b) Mean UPDRS-III ON: 30.9 ± 16.6
(c) Mean UPDRS-III OFF: 34.6 ± 11.9
(iv) Sensory attention subgroup
(a) Mean H&Y Stage: 2.7 ± 0.4
(b) Mean UPDRS-III ON: 37.7 ± 12.0
(c) Mean UPDRS-III OFF: 43.1 ± 8.7

(i) Australian population
(ii) 41 participants
(iii) Anxious subgroup (n � 15)
(a) 11 males; 4 females
(b) Mean age: 66.8 ± 8
(c) Mean PD duration: 12.3 ± 3.6 years
(iv) Asymmetric-motor subgroup
(n � 13)
(a) 8 males; 5 females
(b) Mean age: 68.2 ± 9.3
(c) Mean PD duration: 8.6 ± 4.8 years
(v) Sensory attention subgroups (n � 13)
(a) 10 males; 3 females
(b) Mean age: 70.5 ± 7.8
(c) Mean PD duration: 8.7 ± 4.1 years
(vi) No inclusion or exclusion criteria
directly speciﬁed by paper
(vii) Apart from signiﬁcantly higher
mean UPDRS-III scores in the oﬀ state
compared with the asymmetric-motor
group (F2,35 � 3.64, p � 0.305), no other
statistically signiﬁcant diﬀerences in
baseline demographic information
between the anxiety and remaining
subgroups emerged.

Gilat et al. [42]

(i) An experimental study to
characterize subtypes of freezing of gait
with a newly generated FOG
questionnaire: the C-FOG
(ii) Participants subdivided into 3
categories based on C-FOG results:
asymmetric-motor, anxious, and
sensory-attention
(iii) Baseline assessment data, including
anxiety outcome measures, performed
on all participants

(i) A diagnosis of idiopathic PD by both
a neurologist and movement disorders
specialist
(ii) Freezers
(a) Mean UPDRS-III: 42.7 ± 14
(b) Mean H&Y stage: 2 ± 2 − 4
(iii) Nonfreezers
(a) Mean UPDRS-III: 36.1 ± 11
(b) Mean H&Y stage: 2 ± − 3

PD measures

(i) American population
(ii) Data from 40 PD participants
included in study
(iii) 19 freezers
(a) Gender demographics not
documented
(b) Mean age: 68.4 ± 7.2
(c) Mean PD duration: 9.31 ± 6.6 years
(iv) 21 Nonfreezers
(a) Gender demographics not
(i) A resting state MRI study
documented
investigating functional connectivity
(b) Mean age: 66.9 ± 7.6
diﬀerences in PD patients with and
(c) Mean PD duration: 6.01 ± 4.6 years
without FOG
(v) Inclusion criteria: participants able
(ii) Baseline assessment data, including
to stop taking all dopaminergic
anxiety outcome measures, performed
medication for 12 hours prior to the
on all participants recruited through
experiment
Oregon Health and Science University’s
(vi) Exclusion criteria were as follows:
Parkinson’s Centre of Oregon clinic
unable to safely walk 20 feet without an
aid, previous joint replacement,
musculoskeletal or vestibular disorder,
claustrophobia, severe tremor, and
presence of metal implants
(vii) No signiﬁcant diﬀerences were
found between freezers and nonfreezers
in terms of age (t � 0.645, p � 0.523),
disease duration (t � 0.019, p � 0.985),
and UPDRS-III (t � 1.63, p � 0.111)

Demographic characteristics

Purpose and design

Authors

(i) PAS used to assess anxiety
(ii) Anxious subgroup
(a) Mean PAS: 15.5 ± 6.8
(iii) Asymmetric-motor subgroup
(a) Mean PAS: 9.9
(iv) Sensory attention subgroup
(a) Mean PAS: 13.2 ± 9.6

(i) Items 21 and 9 of PDQ-39
administered for anxiety outcome
measure
(ii) Freezers mean PDQ-39:
(a) Item 21: 1 ± 0 − 2
(b) Item 9: 1 ± 0 − 2
(iii) Nonfreezers mean PDQ-39:
(a) Item 21: 1 ± − 0 − 3
(b) Item 9: 0 ± 0 − 2

Anxiety measures

Table 2: Continued.
Notable results

(i) FOG was assessed with the C-FOG as
well as the FOG-Q total
(ii) Each participant’s gait was assessed
over the course of 8 walking trials, both
ON and OFF dopaminergic medication,
with testing order counterbalanced
across patients. The percentage of
freezing time (%FOG) was also
calculated.
(iii) Anxious subgroup
(a) Mean FOG total: 11.7 ± 3.0 min
(vi) Asymmetric-motor subgroup
(a) Mean FOG total: 10.7 ± 3.3 min
(v) Sensory attention subgroup
(a) Mean FOG total: 11.8 ± 5.3 min
(vi) %FOG was signiﬁcantly positively
related to the anxiety subgroup data
cluster (r � 0.43)—this result formed the
basis of delineating an anxiety subgroup

(i) Mean PAS scores were signiﬁcantly
higher in the anxious subgroup
compared to the asymmetric-motor
(t26 � −2.19, p � 0.038) and sensory
attention (13.2 ± 9.6, t26 � −1.81,
p � 0.082) subgroups
(ii) Signiﬁcantly higher degrees of
freezing
on anxiety-related items of the C-FOG
compared to the motor-related
(t14 � −3.91, p � 0.002) and set shiftingrelated items (t14 � 4.34, p � 0.001)
within the anxious subgroup

(i) No signiﬁcant diﬀerences were
observed between freezers and
nonfreezers for Item 21 of the PDQ-39
(Z � −0.520, p � 0.603)
(i) FOG-Q3 ≥ 1 used to separate freezers
(ii) A trend towards signiﬁcance was
from nonfreezers
exhibited for freezers compared to
(ii) FOG was objectively quantiﬁed
nonfreezers in terms of higher PDQ
through a turning-in-place task with
Item 9 scores (z � −1.79, p � 0.703), but
inertial sensors, allowing the FOG ratio
this ultimately was not signiﬁcant
to be calculated for each participant
(iii) Freezers had signiﬁcantly higher
(iii) Mean FOG ratio
FOG-ratios than nonfreezers (t(38) �
(a) Freezers: 3.21 ± 2.9
3.12, p < 0.001), and worsening FOG
(b) Nonfreezers: 1.04 ± 0.73
severity was associated with greater
degrees of anticoupling between the
amygdala and the frontoparietal
attention control network

FOG measures
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(i) A diagnosis of idiopathic PD made by
a trained neurologist based on UK Brain
Bank Criteria
(ii) Freezers
(a) Mean H&Y stage: 2.77 ± 0.50
(b) Mean UPDRS-III: 37.50 ± 11.44
(iii) Nonfreezers
(a) Mean H&Y stage: 2.29 ± 0.64
(b) Mean UPDRS-III: 32.33 ± 9.84

(i) Serbian population
(ii) 66 patients with PD
(iii) Freezers (n � 30)
(a) No gender demographics
(b) Mean age: 64.90 ± 8.29
(c) Mean PD duration:
11.61 ± 4.42 years
(iv) Nonfreezers (n � 36)
(i) An experimental study performed in
(a) No gender demographics
to explore whether attentional set
(b) Mean age: 64.67 ± 7.16
shifting and inhibitory control were
(c) Mean PD duration: 10.09 ± 5.94
associated with FOG in PD
(v) Healthy age and sex-matched
(ii) Baseline assessment data, including
controls (n � 22)
anxiety outcome measures, performed
(a) No gender demographics
on all participants
(b) Mean age: 65.04 ± 7.64
(iii) Participants were recruited from the
(vi) Inclusion criteria: ≥ 45 years old, an
University of Belgrade’s Institute of
H&Y stage of <4, stable and optimized
Neurology
on antiparkinsonism treatment during
the 4 weeks prior to study initiation and
an MMSE ≥25
(vii) Exclusion criteria: signiﬁcant
comorbidities limiting gait, major
depression according to DSM-IV
criteria, and treatment with
anticholinergic medications

Lagravinese et al.
[43]

Stefanova et al. [41]

(i) HAMA used to assess anxiety
(ii) Freezers
(a) Mean HAMA: 10.07 ± 6.10
(iii) Nonfreezers
(a) Mean HAMA:
8.18 ± 6.10
(iv) Control group
Mean HAMA:
6.45 ± 4.41

(i) BAI used to assess anxiety
(ii) PD FOG+
(a) Mean BAI: 9.35 ± 4.82
(iii) PD FOG−
(a) Mean BAI: 9.87 ± 7.41
(iv) ELD
Mean BAI: 5.42 ± 3.73

Anxiety measures

Table 2: Continued.

(i) A diagnosis of idiopathic PD made by
a trained neurologist based on UK Brain
Bank Criteria
(ii) PD FOG+
(a) Mean H&Y stage: 2.43 ± 0.58
(b) Mean UPDRS-III: 27.18 ± 13.13
(iii) PD FOG−
(a) Mean H&Y stage: 2.05 ± 0.64
(b) Mean UPDRS-III: 20.37 ± 10.27

PD measures

(i) Italian population
(ii) 30 patients with PD
(iii) PD FOG+ (n � 15)
(a) No gender demographics
(b) Mean age: 71.87 ± 4.75
(c) Mean PD duration:
11.20 ± 5.22 years
(iv) PD FOG− (n � 15)
(a) No gender demographics
(b) Mean age: 73 ± 6.31
(c) Mean PD duration:
(i) An experimental study to examine
the eﬀect of emotional stimuli on gait in 10.42 ± 5.34 years
(v) 14 healthy age-matched controls
PD patients with and without FOG
(ii) Baseline assessment data, including (ELD)
(a) No gender demographics
anxiety outcome measures, performed
(b) Mean age: 66.58 ± 6
on all participants
(iii) Participants were recruited from the (vi) Inclusion criteria: an H&Y stage of
University of Genova’s Department of ≤3 and ability to walk unassisted
(vii) Exclusion criteria: MMSE <24,
Neuroscience
history of additional neurological
disorders, and any visual/vestibular/
orthopaedic
impairment that would negatively aﬀect
task performance
(viii) There were no statistically
signiﬁcant diﬀerences between groups
for age (p � 0.15), disease duration
(p � 0.56), H&Y stage (p � 0.15), or
UPDRS-III score (p � 0.23).

Demographic characteristics

Purpose and design

Authors

Notable results

(i) A score of ≥1 on FOG-Q3 used to
separate freezers and nonfreezers
(ii) Two of the following criteria
required for FOG conﬁrmation
(a) Direct observation of FOG by 2
(i) HAMA diﬀerences between the
experienced neurologists
(b) Self-reported FOG by the participant groups were not statistically signiﬁcant
(c) Recognition of past episodes of FOG (p � 0.182)
occurrence when the phenomena was
described by a physician
(iii) Mean FOG-Q total score
(a) Freezers: 12.85 ± 4.88
(b) Nonfreezers: 6.28 ± 5.50

(i) The nFOG was used to delineate the
PD FOG+ and PD FOG− groups, as well
(i) No statistically signiﬁcant diﬀerences
as a measure of FOG severity in the PD
in BAI scores between PD FOG+, PD
FOG+ group
FOG−, and ELD groups (p � 0.08)
(ii) PD FOG+
(a) nFOG-Q total: 15.28 ± 4.50

FOG measures

12
Parkinson’s Disease

Purpose and design

(i) Conﬁrmed diagnosis of idiopathic
PD by a specialist neurologist (who
administered both neurological and
neuropsychological examinations)
(ii) Freezers
(a) Mean H&Y stage: 2.5 ± 0.39
(b) Mean UPDRS-III: 38.91 ± 3.08
(iii) Nonfreezers
(a) Mean H&Y stage: 2.23 ± 0.26
(b) Mean UPDRS-III: 34.18 ± 2.46

(i) A diagnosis of idiopathic PD made by
a trained neurologist based on UK Brain
Bank Criteria
(ii) PD FOG+
(a) Mean H&Y stage: 2.6 ± 0.5
(b) Mean UPDRS-III: 31 ± 9.5 s
(iii) PD FOG−
(a) Mean H&Y stage: 2.4 ± 0.5
(b) Mean UPDRS-III: 30.8 ± 9.5

(i) Italian population
(ii) 29 patients with PD
(iii) PD FOG+ (n � 15)
(a) No gender demographics
(b) Mean age: 72 ± 4.5
(c) Mean PD duration: 10.2 ± 6.3 years
(iv) PD FOG− (n � 14)
(a) No gender demographics
(b) Mean age: 71 ± 4.3
(c) Mean PD duration: 7.9 ± 3.5 years
(v) Healthy age-matched controls
(n � 19)
(a) No gender demographics
(b) Mean age: 71 ± 6.8
(vi) Inclusion criteria: a H&Y stage ≤3,
and an MMSE >24
(vii) PD group exclusion criteria: met
DSM-IV criteria for major depression or
were undergoing treatment via deep
brain stimulation
(viii) Healthy control exclusion criteria:
a diagnosis of PD or other neurological
disorder, major depression, or an MMSE
<24
(ix) There were no statistically
signiﬁcant diﬀerences present between
age or gender between groups (p always
>0.05)

(i) HADS-A used to assess anxiety
(ii) Mean HADS-A scores
(a) Freezers: 7.36 ± 0.90
(b) Nonfreezers: 6.09 ± 1.16
(c) Healthy controls: 5.50 ± 1.63

(i) BAI used to assess anxiety
PD FOG+
(a) Mean BAI: 11.9 ± 10.7
(ii) PD FOG−
(a) Mean BAI: 7.5 ± 6.8
(iii) Control group
Mean BAI: 7.8 ± 6.4

Anxiety measures

Table 2: Continued.
PD measures

Demographic characteristics

(i) Belgian population
(ii) 22 patients with PD
(iii) Freezers (n � 11)
(a) 9 males; 2 females
(b) Mean age: 67.32 ± 2.72
(c) Mean PD duration:
10.45 ± 0.70 years
(iv) Nonfreezers (n � 11)
(i) An experimental study investigating
(a) 9 males; 2 females
executive functioning and attention in
(b) Mean age: 68.20 ± 1.74
PD patients with FOG with participants
(c) Mean PD duration:
Vandenbossche et al.
assessed in their home environment
8.55 ± 1.09 years
[30]
(ii) Baseline assessment data, including
(v) Healthy age-, gender-, and
anxiety outcome measures, performed
education-matched controls (n � 10)
on all participants
(a) 8 males; 2 females
(b) Mean age: 66.10 ± 2.27
(vi) Inclusion criteria: no additional
neurological or orthopaedic disorders
(vii) Exclusion criteria: MMSE <24
(viii) No signiﬁcant diﬀerences were
present between age and gender, with p
values consistently >0.45

(i) An experimental study examining the
relationship between Theory of Mind
and FOG presence in PD patients
(ii) Baseline assessment data, including
Raﬀo De Ferrari et al.
anxiety outcome measures, performed
[15]
on all participants
(iii) Participants recruited from the
University of Genoa’s Department of
Neuroscience

Authors

(i) nFOG used to separate freezers and
nonfreezers with scores >0 meeting
criteria for the freezer group

(i) nFOG was used to separate PD
participants into freezers and
nonfreezers
(ii) FOG presence conﬁrmed via direct
observation by a movement disorders
neurologist in clinic using 360° turning
tasks
(iii) PD FOG+
(a) nFOG-Q total: 11.3 ± 3.9

FOG measures

(i) Group-to-group comparisons of
mean HADS-A scores were not
statistically signiﬁcant (p values
consistently >0.33)
(ii) A correlational analysis revealed
HADS-A score was signiﬁcantly
associated with nFOG-Q total score
(Spearman ρ � 0.81, p � 0.01)

(i) No signiﬁcant main eﬀect for group
was found for the BAI (F(2.47 � 1.39,
p � 0.25)

Notable results
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(i) Serbian population
(ii) 37 patients with PD
(iii) PD-FOG (n � 17)
(a) 10 males; 7 females
(b) Mean age: 64 ± 8
(c) Mean PD duration: 12 ± 5 years
(iv) PD-noFOG− (n � 20)
(a) 12 males; 8 females
(b) Mean age: 63 ± 6
(c) Mean PD duration: 11 ± 4 years
(v) Healthy controls (n � 34)
(i) An experimental MRI study
(a) 20 males; 14 females
exploring patterns of grey matter tissue
(b) Mean age: 64 ± 7
loss in PD patients with FOG
(ii) Baseline assessment data, including (v) Inclusion criteria: ≥ 45 years old, had
anxiety outcome measures, performed an H&Y stage of <4 during the OFF
state, had undergone stable and
on all participants
optimized antiparkinsonism treatment
(iii) Participants were recruited from
during the 4 weeks prior to study
outpatient clinics in the University of
initiation, and had an MMSE ≥25
Belgrade’s Department of Neurology
(vi) Exclusion criteria: signiﬁcant
comorbidities limiting gait, major
depression according to DSM-IV
criteria, treatment with anticholinergic
medications, and underlying focal or
diﬀuse brain damage
(vii) No signiﬁcant diﬀerences in age
(p � 0.75), gender (p � 0.99), and
disease duration (p � 0.23) between
groups

Heremans et al. [40]

Kostić et al. [31]

(i) A diagnosis of idiopathic PD made by
a trained neurologist based on UK Brain
Bank Criteria
(ii) PD-FOG
(a) Mean H&Y stage: 2.7 ± 0.5
(b) Mean UPDRS-III: 39 ± 12
(iii) PD-noFOG
(a) Mean H&Y stage: 2.4 ± 0.6
(b) Mean UPDRS-III: 29 ± 12

(i) An experimental study exploring
handwriting diﬀerences in PD patients
with FOG
(ii) Baseline assessment data, including
anxiety outcome measures, performed
on all participants

(i) HAMA was used to assess anxiety
(ii) Mean HAMA scores
(a) PD-FOGs: 14 ± 11
(b) PD-noFOG: 7 ± 6
(c) Healthy controls: 6 ± 4

(i) HADS-A was used to assess anxiety
(ii) Mean HADS-A scores
(a) Freezers: 7 ± 4
(b) Nonfreezers: 4 ± 4

Anxiety measures

Table 2: Continued.
(i) Belgian population
(ii) 30 patients with PD
(iii) Freezers (n � 15)
(a) 12 males; 3 females
(b) Mean age: 65 ± 9
(c) Mean PD duration: 9 ± 5 years
(iv) Nonfreezers (n � 15)
(a) 10 males; 5 females
(i) A diagnosis of idiopathic PD made by
(b) Mean age: 65 ± 9
a trained neurologist based on UK Brain
(c) Mean PD duration: 8 ± 5 years
Bank Criteria
(v) Healthy age-matched controls
(ii) Freezers
(n � 15)
(a) Mean H&Y stage: 2 ± 0
(a) 5 males; 10 females
(b) Mean UPDRS-III: 40 ± 16
(b) Mean age: 64.3 ± 15
(iii) Nonfreezers
(vi) Inclusion criteria: between H&Y
(a) Mean H&Y stage: 2 ± 0
stages 1–3 during the ON state,
(b) Mean UPDRS-III: 29 ± 9
experiencing writing problems as
indexed by an UPDRS-II item 2.7 score
of >1 and had no additional neurological
disorders or history of depression
(vii) Exclusion criteria: MMSE ≤24,
disease or surgery involving the upper
limb, deep brain stimulation, and vision
problems which impacted performance
on the writing tasks

PD measures

Demographic characteristics

Purpose and design

Authors

(i) A score of ≥1 on FOG-Q3 used to
separate freezers and nonfreezers
(ii) Two of the following criteria
required for FOG conﬁrmation
(a) Direct observation of FOG by 2
experienced neurologists
(b) Self-reported FOG by the
participant
(c) Recognition of past episodes of
FOG occurrence when the phenomena
was described by a physician
(i) FOG-Q total scores were quantiﬁed
(a) Mean FOG-Q total scores
(b) PD-FOG: 16 ± 3
(c) PD-noFOG: 5 ± 3

(i) A nFOG-Q score of ≥1 was used to
delineate the freezer and nonfreezer
groups within PD patients
(ii) Mean FOG-Q total scores
(a) Freezers: 14 ± 8
(b) Nonfreezers: 0 ± 0

FOG measures

(i) Mean HAMA scores were higher in
PD-FOG compared to PD-noFOG
(p � 0.02) and healthy controls
(p � 0.002)

(i) Higher mean HADS-A score
evidenced by the freezers compared to
the nonfreezers was not statistically
signiﬁcant (p � 0.06)

Notable results
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Purpose and design

Demographic characteristics

Rubino et al. [38]

(i) An experimental MRI study
examining diﬀerences in grey matter
volume between PD patients with and
without FOG
(ii) Baseline assessment data, including
anxiety outcome measures, performed
on all participants

(i) Italian population
(ii) 26 patients with PD
(iii) FOG+ (n � 13)
(a) 10 males; 3 females
(b) Mean age: 68.077 ± 8.221
(c) Mean PD duration:
8.154 ± 4.180 years
(iv) FOG− (n � 13)
(a) 9 males; 4 females
(b) Mean age: 68.692 ± 7.664
(c) Mean PD duration:
7.077 ± 2.985 years
(v) Inclusion criteria: treatment with
stable dopaminergic medications, had
appropriate visual acuity and hearing for
the testing procedure, an MMSE >26,
absence of dementia as per Movement
Disorder Society clinical criteria, and no
contraindications to MRI scan
(vi) Exclusion criteria: additional
neurological disorders, uncertain
history of chronic dopaminergic
medication responsiveness, unstable
medical illness, history of alcoholism/
drug abuse/head trauma/mental
disorders, and presence of brain lesions,
tumour, or marked cortical atrophy MRI
(vii) No signiﬁcant diﬀerences in
gender, age, and disease duration
between groups (p values
consistently > 0.42)

(i) Belgian population
(ii) 28 patients with PD
(iii) Freezers (n � 14)
(a) 11 males; 3 females
(b) Mean age: 65.72 ± 7.91
(c) Mean PD duration:
(i) An experimental study that
10.21 ± 2.97 years
investigated whether sequence learning (iv) Nonfreezers (n � 14)
was diminished in PD patients with
(a) 11 males; 3 females
FOG, with participants completing a
(b) Mean age: 68.03 ± 5.11
Vanden bossche et al.
serial reaction time task with random or
(c) Mean PD duration:
[39]
sequenced block conditions
8.21 ± 3.40 years
(ii) Baseline assessment data, including (v) Healthy age-, gender-, and
anxiety outcome measures, performed education-matched controls (n � 14)
on all participants
(a) 11 males; 3 females
(b) Mean age: 67.07 ± 6.64
(vi) Inclusion criteria: no additional
neurological or orthopaedic disorders
and normal or corrected-to-normal
vision
(vii) Exclusion criteria: MMSE <24

Authors

(i) A diagnosis of idiopathic PD made by
a trained neurologist based on UK Brain
Bank Criteria
(ii) FOG+
(a) Mean H&Y stage: 2.423 ± 0.400
(b) Mean UPDRS-III: 17.846 ± 6.22
(iii) FOG−
(a) Mean H&Y stage: 2.307 ± 0.325
(b) Mean UPDRS-III: 17.230 ± 2.77

(i) Conﬁrmed diagnosis of idiopathic
PD by a specialist neurologist (who
administered both neurological and
neuropsychological examinations)
(ii) Freezers
(a) Mean H&Y stage: 2.43 ± 0.416
(b) Mean UPDRS-III: 37.21 ± 15.99
(iii) Nonfreezers
(a) Mean H&Y stage: 2.43 ± 0.319
(b) Mean UPDRS-III: 35.64 ± 9.10

PD measures

(i) HAMA used to quantify anxiety
(ii) Mean HAMA scores
(a) FOG+: 6.154 ± 3.95
(b) FOG−: 6.385 ± 4.46

(i) HADS-A used to assess anxiety
(ii) Mean HADS-A scores
(a) Freezers: 6.57 ± 3.13
(b) Nonfreezers: 5.64 ± 3.56
(c) Healthy controls: 5.29 ± 5.54

Anxiety measures

Table 2: Continued.

(i) HADS-A scores were not
signiﬁcantly diﬀerent between groups
(p � 0.693, p � 0.019)

Notable results

(i) Participants were classiﬁed as FOG+
if they had a score of ≥1 on the FOG-Q3
and direct observation of FOG by 2
(i) Mean HAMA scores were not
experienced neurologists or self-report
signiﬁcantly diﬀerent in FOG+ vs.
of FOG by participant and/or the
FOG− (p � 0.890)
recognition of past episodes of FOG
when the phenomena was described by a
physician

(i) nFOG used to separate freezers and
nonfreezers with scores >0 meeting
criteria for the freezer group

FOG measures
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(i) Brazilian population
(ii) 78 patients with PD
(iii) Freezers (n � 27)
(a) 16 males; 11 females
(b) Median age: 71 (61–85)
(c) Median PD duration: 9.0 (2–20)
(iv) Nonfreezers (n � 51)
(a) 26 males; 25 females
(i) An observational cross-sectional
(b) Median age: 68 (60–89)
study examining the relationship
(c) Median PD duration: 4.0 (1–14)
between anxiety and FOG in PD
(v) Inclusion criteria: able to walk
(ii) Several self-report measures were
without the assistance of another person
administered to PD patients with and
(with or without a gait aid)
without FOG, including anxiety
(vi) Exclusion criteria: atypical
outcome measures
(iii) Participants were recruited from a parkinsonism, dementia, severe visual or
movement disorders clinic the State of auditory disturbance, and presence of
Bahia Health Attention for the Elderly in comorbidities that aﬀected balance and
gait.
Brazil
(vii)Freezers were signiﬁcantly older
than nonfreezers (p � 0.010), had
signiﬁcantly longer disease durations
than nonfreezers (p < 0.001), and the
gender composition of each group was
not signiﬁcantly diﬀerent (p � 0.485)
(data are shown as median (range))

Pimenta et al. [33]

Demographic characteristics

Purpose and design

Authors

(i) A diagnosis of idiopathic PD made by
a trained neurologist based on UK Brain
Bank Criteria
(ii) Freezers
(a) Median H&Y stage: 3.0 (2–4)
(b) Mean UPDRS-III: 39.8 ± 9.9
(ii) Nonfreezers
(a) Median H&Y stage: 2.5 (1.5–3)
(b) Mean UPDRS-III: 28.4 ± 11.7

PD measures

(i) Anxiety subscale of HADS (HADSA) subtotalled and compared between
groups with scores ≥ 8 meeting criteria
for anxiety disorder
(ii) Freezers
(a) Number of PD patients with
HADS-A ≥ 8: 19 (70% of freezers)
(iii) Nonfreezers
(a) Number of PD patients with
HADS-A ≥ 8: 16 (31% of nonfreezers)

Anxiety measures

Table 2: Continued.
Notable results

(i) Signiﬁcantly higher proportions of
freezers had a HADS-A score ≥ 8 than
nonfreezers (p � 0.001)
(ii) Correlation analysis demonstrated a
signiﬁcant relationship between HADSA and FOG-Q3 (rho � 0.44, p < 0.001)
and FOG severity (rho � 0.36, p � 0.001)
(iii) Univariate regression analysis
(i) Freezers were classiﬁed based on a
showed a signiﬁcant association between
FOG-Q3 score of ≥1
HADS-A and FOG severity (B � 2.92,
(ii) FOG items 3–6 score used to assess
95% CI: 1.24–4.59, p � 0.001)
FOG severity
(iv) Multivariate linear regression
analysis also indicated a signiﬁcant
relationship between HADS-A ≥8 and
FOG severity (B � 1.89, 95% CI:
0.47–3.31, adjusted R2 � 0.385,
p � 0.010) with a HADS-A score of ≥8
accounting for 38% of the variance in
FOG severity scores

FOG measures
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(with the exception of [22, 23, 32, 34], which used Item 14 of
the UPDRS-II as their measure of self-reported FOG). The
entire FOG-Q is a 6-item questionnaire with 4 questions
speciﬁc to FOG severity and 2 questions about general gait
diﬃculties, with responses graded on a 5-point scale from 0
to 4 [8]. The 3rd item of this questionnaire (Do you feel that
your feet get glued to the ﬂoor while walking, making a turn,
or trying to initiate walking (i.e., freezing)?) is often used
alone, with a score ≥1 meeting criteria for FOG in several
studies.
Six studies implemented a new version of the Freezing of
Gait Questionnaire (nFOG-Q) that was designed by
Nieuwboer et al. [17] to better assess FOG severity in PD
patients which was largely based on the original FOG-Q. The
nFOG-Q adds an additional item to the beginning of the
FOG-Q that “allows FOG detection and exclusion of patients
without the symptom from the actual scoring of FOG severity and impact” [17] and a video presentation demonstrating variants of FOG for patients/caregivers. Ehgoetz
Martens et al. [29] implemented a newly designed Characterizing Freezing of Gait questionnaire (C-FOG)—a 35item self-reported scale divided into 4 sections: severity,
triggers, strategies (to reduce or overcome FOG), and other
types of freezing (i.e., upper limb freezing) [29]. Based on the
C-FOG responses, PD patients with FOG are further divided
into asymmetric motor, anxious, and sensory-attention
freezing subtypes.
Objective measures of FOG were also collected during
some experimental paradigms through either virtual reality
paradigms, gait tasks, positional sensors, or some combinations thereof.
3.5. Positive Studies. Sixteen of the 26 studies demonstrated
a signiﬁcant relationship between their respective anxiety
outcome measure and FOG presence and/or severity,
therefore meeting criteria for a positive result. However, the
studies diﬀer extensively in their methodology including
diﬀerent anxiety measures, study design, and FOG quantiﬁcation. Their details are given below.
3.5.1. Zhang et al. [18]: A Three-Year Prospective Longitudinal Study in a Chinese Population. There was no significant association between the total HAMA, HAMA Somatic
Anxiety, and HAMA Psychic Anxiety baseline scores and
development of FOG 3 years after study. In contrast, the
HAMD Anxiety/Somatic score was signiﬁcantly higher in
PD patients with FOG than that in PD patients without FOG
3 years after study. Further binary logistic regression
revealed that the HAMD Anxiety/Somatic score was signiﬁcantly associated with FOG development 2 years later,
but not 1 year later or 3 years later. Ultimately, the study
concluded no signiﬁcant associations between HAMA
scores and FOG but discovered higher scores on the HAMD
Anxiety/Somatic subscale were signiﬁcantly associated with
the presence of FOG 2 years later. Risk factors for the development of FOG changed yearly in this patient population
and comprised a combination of nonmotor and motor
symptomatology.
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3.5.2. Ehgoetz Martens et al. [19]: A Prospective Longitudinal
Study Conducted on a Larger Cohort of Cases in an Australian Population. The mean HADS-A score in PD + FOG
was signiﬁcantly higher than that in PD-NF, with a signiﬁcant main eﬀect of group observed. This group eﬀect
remained signiﬁcant with additional covariate analysis using
the UPDRS-III score, mean PD duration, and MMSE score
as covariates. In contrast, the mean HADS-A score in
PD + mild FOG was not signiﬁcantly diﬀerent from that in
PD + FOG. A signiﬁcant correlation between the severity of
anxiety symptoms and FOG-Q3 scores emerged across all
groups.
Further analysis to assess the predictive value of the
HADS-A score for the presence of FOG in PD involved
merging the original PD + mild FOG and PD + FOG
groups into one single PD + FOG group, with the original
PD-NF group remaining intact during comparison. This
ﬁnal analysis revealed a positive predictive value of 28.26%
for identifying patients with FOG and a negative predictive value of 89.61% for identifying patients without
FOG. This study concluded a signiﬁcant relationship
between anxiety and presence of FOG and implicated
anxiety as a potential biomarker for FOG development in
PD patients.
3.5.3. Walton et al. [20]: A Cross-Sectional Analysis of
Baseline Assessment Data from the University of Sydney’s
Parkinson’s Disease Research Clinic. HADS-A scores were
signiﬁcantly correlated with FOG severity. The study’s main
conclusion centred on self-reported FOG as a signiﬁcant
independent contributor to quality of life in PD and evidenced a statistically signiﬁcant relationship between anxiety
and FOG severity through self-reported measures.
3.5.4. Ou et al. [21]: An Observational Cross-Sectional Study
in a Chinese Population to Explore the Prevalence and
Clinical Correlates of FOG. In analysis of covariance
adjusting for age, disease duration, and H&Y stage, the total
mean score on the HAMA for freezers was signiﬁcantly
higher than that for nonfreezers. A binary logistic regression
analysis indicated no signiﬁcant correlation between the
HAMA anxiety score and FOG. Notably, age- and disease
duration-adjusted ANOVA indicated that the freezers had
lower total scores on the MMSE and Montreal Cognitive
Assessment compared to nonfreezers, and lower MMSE
scores were not excluded from the ﬁnal analysis. The study
ultimately concluded that while mean HAMA anxiety scores
were signiﬁcantly higher in freezers than those in nonfreezers, HAMA was not a signiﬁcant clinical correlate related to FOG.
3.5.5. Burn et al. [22]: An Observational Cross-Sectional
Study in a UK Population That Sought to Identify Associations between Phenotypic Variants of Motor and Mood
Subtypes in PD. The mean total HADS-A score in freezers
was signiﬁcantly higher than that in nonfreezers, with a
signiﬁcantly higher proportion of freezers meeting the
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HADS-A ≥ 11 criteria for anxiety compared to nonfreezers
(20%). Follow-up logistic regression analysis revealed that an
HADS-A score ≥11 (Class 3) was not signiﬁcantly predicted
by FOG status.
3.5.6. Lieberman [23]: An Observational Cross-Sectional
Study in a US Population to Study the Association between
Anxiety, Depression, and Panic Attacks in PD Patients with
FOG. Freezers in this study population had signiﬁcantly
higher HAMA scores compared to nonfreezers. Additionally, panic attacks were signiﬁcantly increased in freezers
compared to nonfreezers. Ultimately, FOG presence in PD
was signiﬁcantly associated with anxiety and panic attacks in
this study.

3.5.7. Yao et al. [24]: A Case-Control Study in a Chinese
Population Investigating Whether Cognitive Impairment Was
Correlated with FOG in PD Patients. After adjusting for age,
no signiﬁcant diﬀerences were found between HAMA total,
HAMA Somatic Anxiety, and HAMA Psychic Anxiety between freezers and nonfreezers, but the HAMD Anxiety/
Somatic score was signiﬁcantly higher in freezers than that in
nonfreezers. Spearman’s rho correlation between HAMD-A
and nFOG-Q demonstrated severity of FOG positively
correlated with higher anxiety subscale scores within the
FOG subgroup. Though the study indicated no signiﬁcant
relationship between HAMA and FOG in PD, the HAMD
Anxiety/Somatic score was signiﬁcantly related to FOG
status.
3.5.8. Rahimi et al. [25]: A Prospective, Experimental, Pre/
Posttreatment Study in a Canadian Population Wherein
Optimally Medicated PD Patients with Intractable FOG Were
Treated with a 90-Day Course of 1 mg of Rasagiline per Day,
with FOG Frequency/Duration and Cognitive/Motor Measures Assessed prior to and following Treatment. A hierarchical clustering analysis was utilized to identify subgroups
of participants with similar responses to rasagiline therapy
based on FOG frequency and duration. Subsequently,
participants were divided into the following three groups
following treatment with rasagiline: improved (n � 6),
worsened (n � 5), and no change (n � 3). There were no
signiﬁcant diﬀerences in pre/posttreatment BAI scores, or
overall count and duration of FOG episodes. The high
variability in individual scale scores led to null eﬀects across
measures.
As the no-change group did not exhibit any episodes of
FOG, they were excluded from follow-up bidirectional
elimination-stepwise regression analysis (thereby avoiding
ﬂoor eﬀects) to identify the clinical variables which predicted
reduction in frequency of FOG events after treatment.
Higher BAI scores proved to be a statistically signiﬁcant
predictor of FOG worsening following rasagiline therapy,
and the ﬁnal predictive model explained 99% of the variance
between the improved and worsened groups as a function of
treatment with rasagiline.
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3.5.9. Ehgoetz Martens et al. [26]: A Longitudinal Study
Conducted in an Australian Population. HADS-A scores
increased signiﬁcantly from baseline to follow-up across all 3
groups, and both continuing and transitional freezers had
signiﬁcantly greater mean HADS-A scores compared to
nonfreezers at baseline and follow-up. Correlational analysis
revealed HADS-A scores were signiﬁcantly associated with
FOG-Q total scores.
A predictive model was constructed with FOG-Q total
and HADS-A among the 7 predictive variables included, the
overall predictive success of which was 84% (correctly
classiﬁed 69.6% of transitional freezers and 90.4% of nonfreezers). Since FOG-Q total and HADS-A were the
strongest predictors identiﬁed in this model, a subsequent
model was constructed that only included these two variables to enhance clinical relevance. This ﬁnal model was able
to correctly identify 64.9% of patients who developed FOG
and 90% of patients who remained nonfreezers with an
overall predictive success of 82.1%. The study concluded that
anxiety was a crucial variable to consider in accurately
predicting the onset of FOG in PD patients and suggested
HADS-A scores may be a useful screening tool for clinicians
to identify patients at risk for FOG development.
3.5.10. Ou et al. [27]: A Longitudinal Study in a Chinese
Population to Evaluate Clinical Predictors of FOG. In this
sample, signiﬁcantly higher mean HAMA scores at baseline
and follow-up were observed in freezers compared to
nonfreezers; however, the annual change in the HAMA
score did not diﬀer signiﬁcantly between the two groups.
Ultimately, the HAMA score was not determined to be a
signiﬁcant predictor of FOG development in this cohort,
though HAMA scores were higher in freezers.
3.5.11. Ehgoetz Martens et al. [28]: An Experimental TaskBased Functional MRI Study in an Australian Population to
Investigate the Neural Heterogeneity of Freezing of Gait.
Higher degrees of functional connectivity between the
limbic network and the ventral striatum as well as the
cognitive control network (comprising the anterior cingulate cortex, dorsolateral prefrontal cortex, and posterior
parietal cortex) during freezing episodes were observed
compared to normal foot tapping. Higher HADS scores were
associated with this increased coupling. Anticoupling
among the cortical and subcortical regions of the limbic
network (and within the subcortical limbic region itself ) was
also noted during freezing relative to normal foot tapping,
and this degree of anticoupling was also associated with a
higher HADS score. Subcortical regions of the limbic network demonstrated tight coupling to the dorsal caudate
(whereas the cognitive control network and the dorsal
caudate nucleus were anticoupled). Lower HADS scores
corresponded with less functional connectivity between the
cortex and striatum. Ultimately, the study concluded that
three unique phenotypes of gait freezing exist (cognitive,
motor, and limbic), with functional neuroimaging of the
limbic corticostriatal pathway suggesting a distinct limbic
phenotype of FOG that was related to HADS scores.
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3.5.12. Ehgoetz Martens et al. [29]: An Experimental Study
Performed in an Australian Population to Characterize
Subtypes of Freezing of Gait with a Newly Generated FOG
Questionnaire (C-FOG). Higher mean PAS scores were
observed in the anxious subgroup compared to the asymmetric-motor and sensory-attention subgroups. The study
concluded that distinct freezing phenotypes could be
identiﬁed using the C-FOG, with signiﬁcantly higher PAI
scores characterizing the anxiety subgroup.
3.5.13. Vandenbossche et al. [30]: A Belgian Study Investigating Executive Functioning and Attention in PD Patients with FOG. The HADS-A was signiﬁcantly associated
with nFOG-Q total scores. The study concluded that an
impairment in conﬂict resolution was signiﬁcantly associated with FOG in PD and evidenced a signiﬁcant correlation
between FOG severity and HADS-A scores.
3.5.14. Kostic et al. [31]: An MRI Study in a Serbian Population to Explore Patterns of Grey Matter (GM) Tissue Loss
in PD Patients with FOG. Mean HAMA scores were higher
in PD-FOG than those in PD-noFOG and healthy controls.
Ultimately, the study discovered a pattern of GM atrophy in
the frontal and parietal cortices associated with FOG
presence and reported signiﬁcantly higher HAMA scores in
PD patients with FOG.
3.5.15. Ehgoetz Martens et al. [32]: A Canadian Study Where
Anxiety Was Induced via a Virtual Reality Apparatus and the
Presence/Severity of FOG Subsequently Measured in PD
Patients Both on and oﬀ Dopaminergic Medications. The
primary outcome measure that quantiﬁed FOG was the
percent of each trial frozen, with freezers spending a signiﬁcantly greater portion of time frozen in the high condition compared to the low condition. In addition, freezers
exhibited signiﬁcantly higher numbers of freezing episodes
in the high condition relative to the low condition, but no
signiﬁcant diﬀerences in the duration of freezing. Concomitantly, freezers self-reported signiﬁcantly higher levels
of anxiety during the experiment compared to nonfreezers,
with both groups reporting signiﬁcantly higher levels of
anxiety in the high condition compared to the low condition.
Anxiety severity was signiﬁcantly higher when freezers were
tested oﬀ their dopaminergic medications compared to on
medications, and none of the FOG variables were statistically
compared between medication states secondary to the
limited dataset and lack of variance.
This study concluded that anxiety plays a causal role in
FOG. By manipulating anxiety-inducing condition via virtual reality, Ehgoetz Martens et al. [32] were able to elicit
over 300 freezing episodes in 85.7% of PD patients with
FOG—a feat previously unheard of in the literature. The
high condition resulted in a signiﬁcantly higher number of
FOG episodes and percentage of time frozen compared to
the low condition in the freezing population, with freezers
reporting signiﬁcantly higher levels of anxiety compared to
nonfreezers. Neural correlates were inferred based on these
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ﬁndings in conjunction with prior neuroimaging studies of
FOG patients, which implicated disrupted emotive processing in the ventral striatum and anxiety-induced limbic
overactivity as potential mechanisms underlying FOG.
3.5.16. Pimenta et al. [33]: A Cross-Sectional Study in a
Brazilian Population Examining the Relationship between
Anxiety and FOG in PD. HADS-A scores were signiﬁcantly
higher in freezers than those in nonfreezers, and HADS-A
scores were signiﬁcantly correlated with both FOG-Q3 and
FOG severity. HADS-A scores ≥8 were determined to accounting for 38% of the variance in FOG severity scores in
this study population. The study concluded that the HADSA was an independent contributor to FOG severity and
recommended routine anxiety evaluations in PD patients
presenting with FOG.
3.6. Negative Studies. Ten of the 26 studies evidenced no
signiﬁcant relationship between their respective anxiety
outcome measure and FOG presence and/or severity,
therefore meeting criteria for a negative result. Once again,
the studies diﬀer extensively in their methodology including
diﬀerent anxiety measures, study design, and FOG quantiﬁcation. Their details are given below.
3.6.1. Perez-Lloret et al. [34]: An Observational Cross-Sectional Study Conducted in France to Determine the Prevalence of FOG in a Sample of PD Patients and Assess Its
Relation to Quality of Life-Related Clinical Correlates (including Anxiety). No signiﬁcant diﬀerences in HADS-A
scores between freezers and nonfreezers were found. The
study ultimately concluded that FOG in PD patients correlates with reduced quality of life, disease severity, cognitive
deﬁcit, and exposure to antimuscarinics, but no correlation
was found with presence of anxiety in this study population.
3.6.2. Hall et al. [35]: A Cross-Sectional Analysis of Baseline
Assessment Data Gathered from a Larger Cohort of Cases at
the University of Sydney’s Parkinson’s Disease Research
Clinic from 2008 to 2015. Though the mean HADS-A score
was higher in freezers than that in nonfreezers, this difference did not prove to be statistically signiﬁcant following Mann–Whitney’s U-test. The study concluded
early-stage PD patients with FOG had increased nontremor motor features (speech, swallowing, facial expression diﬃculties, etc.) and selective impairments of
working memory/attentional set-shifting, but not significantly increased anxiety levels compared to nonfreezers in
this study population.
3.6.3. Huh et al. [36]: A Case-Control Cross-Sectional Experiment in a South Korean Population Examining Postural
Sensory Deﬁcits Linked to FOG Severity through a Computerized Dynamic Posturography System. PD patients with
FOG and PD patients without FOG had signiﬁcantly higher
BAI scores compared to controls with no signiﬁcant
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diﬀerences between groups. The authors concluded that
speciﬁc postural sensory deﬁcits (i.e., disrupted somatosensory feedback and vestibular input integration) were
associated with FOG in PD, but BAI scores were not.
3.6.4. Raﬀo De Ferrari et al. [37]: An Experimental Study
Conducted in an Italian Population Examining the Relationship between Theory of Mind and FOG Presence in PD
Patients. No signiﬁcant main eﬀect of group was found for
BAI scores. The study concluded that aﬀective theory of
mind was impaired in the PD-FOG+ group compared to the
PD-FOG− group, but no signiﬁcant diﬀerences for selfreported anxiety were apparent.
3.6.5. Rubino et al. [38]: An Italian Study Examining Differences in Grey Matter Volume (GM) between PD Patients
with and without FOG. The mean HAMA score was higher
in the FOG− group than that in the FOG+ group, but this
diﬀerence was not statistically signiﬁcant. The study localized the posterior parietal cortex as a site of cortical volume
reduction in FOG+ participants relative to the FOG− group,
but these groups did not diﬀer signiﬁcantly in their HAMA
scores.
3.6.6. Vandenbossche et al. [39]: A Belgian Study That Investigated Whether Sequence Learning Was Diminished in
PD Patients with FOG, with Participants Completing a Serial
Reaction Time Task with Random or Sequenced Block
Conditions. Though the mean HADS-A score was higher in
freezers than that in nonfreezers and controls, an independent t-test did not yield any statistically signiﬁcant
diﬀerences between these groups. The study discovered
signiﬁcant impairments in automaticity in PD patients with
FOG, but no signiﬁcant diﬀerences or association between
anxiety levels and FOG in PD patients.
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3.6.9. Gilat et al. [42]: A Resting-State MRI Study Investigating Functional Connectivity Diﬀerences in PD Patients with and without FOG in an American Population.
Worsening severity of FOG was associated with greater
degrees of anticoupling between the amygdala and regions of
the frontoparietal attention control network. Item 21 of
PDQ-39 was not signiﬁcantly correlated with the functional
connectivity scores in freezers and nonfreezers. A signiﬁcantly negative association between Item 9 of the PDQ-39
and the functional connectivity between the bilateral
amygdala and the frontoparietal attention control network
was discovered in freezers, but not nonfreezers. No other
statistically signiﬁcant functional connectivity relationships
emerged between Item 9 scores in freezers and nonfreezers.
The study ultimately provided neuroimaging evidence for
increased baseline striato-limbic connectivity in freezers
compared to nonfreezers. The anxiety outcome measure
(Item 21 of PDQ-39) was not signiﬁcantly diﬀerent in
freezers vs. nonfreezers and did not correlate signiﬁcantly
with striato-limbic connectivity, with the study authors
noting a thorough assessment of mood disturbance had not
been performed and recommending further research to
explore the underlying pathophysiology of anxiety-induced
FOG.
3.6.10. Lagravinese et al. [43]: An Experimental Study Performed in an Italian Population to Examine the Eﬀect of
Emotional Stimuli on Gait in PD Patients with and without
FOG. Mean BAI scores were lower in the PD-FOG+ group
than those in the PD-FOG− group and higher than those in
the ELD group. These diﬀerences were not statistically
signiﬁcant. The study concluded that emotional valence of
stimuli aﬀected gait initiation in the PD-FOG+ group
compared to PD-FOG– patients and healthy controls, but
anxiety measures did not diﬀer signiﬁcantly between these
groups.

4. Discussion
3.6.7. Heremans et al. [40]: A Study Conducted in a Belgian
Population to Explore Handwriting Diﬀerences in PD Patients with FOG. The mean HADS-A score was higher in
freezers than that in nonfreezers, but this diﬀerence was
not statistically signiﬁcant. The study discovered writing
was more severely negatively impacted in PD patients with
FOG compared to PD patients without FOG, and the
HADS-A scores did not diﬀer signiﬁcantly between these
groups.
3.6.8. Stefanova et al. [41]: An Experimental Study Performed
in a Serbian Population to Explore Whether Attentional SetShifting and Inhibitory Control Were Associated with FOG in
PD. HAMA diﬀerences between freezers and nonfreezers
were not statistically signiﬁcant. The study concluded speciﬁc attentional set-shifting dysfunctions were associated
with FOG in PD, but no signiﬁcant diﬀerences were apparent in anxiety measures between freezers, nonfreezers, or
healthy age- and sex-matched controls.

To our knowledge, this is the ﬁrst systematic literature review to summarize research ﬁndings on the association
between anxiety and freezing of gait in PD. Most studies
revealed that higher ratings on anxiety subscales were signiﬁcantly correlated with FOG presence in PD and/or severity, with 16 of the 26 studies indicating a relationship
between anxiety outcome measure and presence or severity
of FOG.
4.1. Design. Nine of the included studies used age-matched
controls: [24, 30, 31, 36, 37, 39–41, 43]. Of these studies, only
Vandenbossche et al. [30] and Kostic et al. [31] reported
statistically signiﬁcant diﬀerences between anxiety outcome
measures and FOG severity. Apart from Yao et al. [24], the
primary focus of these age-matched control group studies
was not anxiety. This review lacks a consistent evidence base
of research comparisons to age-matched controls, and a
comparator control group with anxiety levels as the primary
objective of the research is greatly needed in further research
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of this topic. Additionally, 46% of the reviewed studies were
observational in nature (n � 12). Of these observational
studies, nine found a signiﬁcant relationship between FOG
presence or severity and anxiety outcome measure in PD
patients, but only four of these had a longitudinal design.
More prospective longitudinal designs are needed to further
examine the causative role of anxiety in FOG development.
4.2. Anxiety. Signiﬁcant heterogeneity existed in terms of
the anxiety subscales used. Conﬂicting reports exist regarding the validity of these subscales in PD. The HADS-A,
while useful as a screening tool for anxiety, has been criticized for lack of speciﬁcity in distinguishing depressive and
anxiety symptoms in PD [44]. A Rasch analysis performed
by Forjaz et al. [45] determined that the HADS-A was not
suitable for assessing anxiety in PD, and evidence from
multiple review articles corroborates this ﬁnding [46, 47]. A
systematic literature review of studies that performed a
latent factor analysis of the HADS published between 2000
and 2010 suggested that both its underlying structure and
ability to detect depression or anxiety were uncertain [48].
Given that the HADS-A was the most commonly implemented anxiety outcome measure in this literature review, the
questions of its applicability to PD are particularly relevant. Six
of the eleven studies that implemented the HADS-A in this
literature review demonstrated a signiﬁcant relationship between FOG and anxiety: [19, 20, 22, 26, 30, 33]. Ultimately, an
inconsistent pattern emerged with a wide range of associations
between HADS-A and FOG presence/severity. On the one
hand, Ehgoetz Martens et al. [26] and Pimenta et al. [33]
suggested that the HADS-A score could potentially be a
screening tool for FOG development based on the high
predictive power of the score in their sampled populations,
while on the other hand, Perez-Lloret et al. [34] and Hall
et al. [35] reported no signiﬁcant HADS-A diﬀerences
between freezers and nonfreezers in their cohorts. Furthermore, Perez-Lloret et al. [34] required a score ≥7 on the
scale to meet study criteria for anxiety, Pimenta et al. [33]
required a score ≥8, and Burn et al. [22] required a score
≥11. A more consistent consensus on speciﬁc HADS-A
criteria for anxiety would facilitate direct comparisons
between studies more eﬀectively, and more research needs
to investigate both its suitability for PD patients and its
association with FOG.
These same points can be made in relation to the other
anxiety scales used. While some literature recommends the
BAI as a more comprehensive and valid assessment of
anxiety symptoms in PD [46], others report unsatisfactory
interitem correlation, convergent validity, and factorial
structure [49]. It is also noted that the BAI’s item content is
weighted towards physical symptoms of panic attacks as
opposed to generalized anxiety. While the BAI showed some
promising utility in Rahimi et al.’s small sample in predicting
FOG treatment success [25], the remaining three studies that
incorporated the BAI did not demonstrate a signiﬁcant
relationship between anxiety and FOG presence, and the
conﬂicting evidence of its validity in PD is reminiscent of the
issues encountered with the HADS-A. The same can be said
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for the HAMA—the second most common anxiety scale
used in our review. Leentjens et al. [44] determined that the
HAMA possessed satisfactory interitem correlation, convergent validity, and factorial structure. However, the
positive predictive value of 0.63 was deemed poor. HAMA
has also been criticized for bias towards persistent symptoms
of anxiety as opposed to episodic anxiety or avoidance
behaviour [49]. In our literature review, a signiﬁcant association between HAMA and gait freezing was reported
in three of the eight papers that used it (Ou et al. [21],
Lieberman [23], and Kostic et al. [31]).
Many of the studies that used the HAMA also used the
HAMD—a scale designed to quantify depressive symptoms.
While we did not include the total HAMD score as part of
our analysis, the HAMD-A component of the scale was
investigated and reported in our results. Much like the
HAMA, a factor analysis of the HAMD in PD revealed an
unsatisfactory factorial validity, questioning its ability to
assess the anxiety domain of the subscale in PD [50]. An
interesting ﬁnding emerged in both Zhang et al. [18] and Yao
et al.’s [24] papers: FOG development was associated with
HAMD-A, but not HAMA scores. We considered this a
positive relationship between anxiety and FOG for the
purposes of this literature review, but these discordant
ﬁndings between scales that are designed to measure similar
symptoms speak to the issue of variable anxiety detection as
a function of scale. In addition, these contrast with Ou et al.
[21], Lieberman [23], and Kostic et al.’s [31] results wherein
HAMA scores were signiﬁcantly higher in freezers than
those in nonfreezers. It is thus still unclear whether FOG is
signiﬁcantly linked to HAMA scores.
Of the remaining scales, the STAI used in Ehgoetz
Martens et al.’s study [32] has evidence of discriminant and
convergent validity [51], but consensus exists in the literature that its applicability to PD needs to be investigated
further [46, 47]. Interestingly, no signiﬁcant diﬀerences
between PD patients with and without FOG were illustrated
by the baseline STAT-I in their study, but self-reported
anxiety (collected on the manikin during the virtual reality
task) was signiﬁcantly higher in freezers than that in nonfreezers. This ﬁnding suggests that capturing anxiety in FOG
is multifaceted and may require a more comprehensive
anxiety assessment to adequately assess the phenomena.
Similarly, Gilat et al. [42] acknowledge in their paper that
their ﬁnding of no signiﬁcant group diﬀerence between
freezers and nonfreezers in Item 21 of PDQ-39 may be
secondary to not thoroughly assessing the baseline mood
disturbance of the participants. Using this single 5-point
question to quantify anxiety is limited in scope, and more
comprehensive measures should be used when assessing
anxiety in this context.
Finally, Leentjens et al. [49] developed the Parkinson
Anxiety Scale (PAS) used by Ehgoetz Martens et al. [29]. This
is the most recently developed anxiety scale of the six and
reportedly possesses superior validity and encompasses PDspeciﬁc anxiety symptoms more eﬀectively by assessing
three types of anxiety: persistent, episodic, and avoidant. The
signiﬁcant association between PAS scores and the anxious
subgroup of gait freezers identiﬁed by Ehgoetz Martens et al.
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[29] warrants further study to further explore the validity
and reliability of this scale. The Geriatric Anxiety Inventory
is another scale that has been recommended speciﬁcally for
use in PD patients [47] but was not used by the studies in this
literature review. In light of neuroimaging data that suggest
the HAMA and STAT-I measure diﬀerent aspects of anxiety
[52] (with the HAMA related to the subclinical expression of
anxiety disorders and the STAT-I related to underlying
personality characteristics conducive to anxiety), it is important to implement a scale that fully accounts for diﬀerent
anxiety variants, standardize the anxiety outcome measure
that is ultimately used, and ensure its construct validity is
suitable for PD patients with FOG in future research.
4.3. FOG. Thirteen studies implemented diﬀering approaches to FOG identiﬁcation, in that FOG was deemed
present by either self-reported measures, family member
accounts, or direct neurologist observation. This variable
approach to detection stems from the episodic nature of
FOG, a characteristic which reportedly makes detection of
the phenomena diﬃcult, impedes standardization of assessment, and limits generalizability of research [53]. In
keeping with this, multiple studies in this review list recall
bias secondary to self-reported measures of FOG as a
limiting factor in their respective papers [18, 20, 21]. Although portions of the UPDRS and FOG-Q are convenient,
valid, and widely used tools for assessing FOG symptoms in
large numbers of participants, the potential for observation
bias is well documented [46]. Seven papers in this review
implemented the nFOG-Q, a scale largely based on the FOGQ which shares the same susceptibility to recall bias.
However, Nieuwboer et al. [17] report that the nFOG-Q is a
reliable tool to screen FOG and can detect FOG that has
previously occurred in the home environment—a beneﬁt not
conferred by experimental paradigms which elicit FOG in a
laboratory setting.
Six of the studies [25, 28, 29, 32, 36, 42] approached the
issue of FOG detection by combining self-reported measure
with direct observation in a laboratory setting. This approach
is in keeping with recommendations of Nonnekes et al. [54],
who posit that both objective and subjective measures of
FOG are necessary to account for the multifactorial nature
by which FOG presents. This also allows for an appropriate
degree of standardization. Each study implemented a different protocol for their objective FOG measurements, and
all six corroborated their experimental ﬁndings with selfreported measures. In this subset of studies, four out of six
demonstrated a signiﬁcant relationship between FOG and
anxiety. These studies are especially innovative with their
various approaches to objectively measuring and at times
consistently inducing FOG.
A standardized method of FOG elicitation and assessment that combined subjective and objective measures
would allow more direct comparisons between studies to be
drawn. Notably, the newly designed C-FOG used by Ehgoetz
Martens et al. [29] delineates multiple phenotypes of FOG,
and the signiﬁcant ﬁndings of this paper warrant attention.
A more comprehensive and nuanced assessment of FOG
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presentation, standardization of these scales in future research on anxiety and FOG, and consistency in outcome
measurements mark important future directions of research
that could identify anxiety as a potential treatable biomarker
in the pathogenesis of FOG [29].
4.4. Neural Correlates. Neuroimaging research included in
the review largely supports the implication of anxiety as both
a prodromal symptom of PD and an important independent
contributor to FOG pathogenesis. The cross-talk model
suggests that increased limbic load (secondary to higher
levels of anxiety and competing inputs) could precipitate
FOG by overloading the striatum, interfering with normal
basal ganglia motor processing [55]. This model aligns with
the neuroimaging results from the study of Ehgoetz Martens
et al. [28], Gilat et al. [42], and Rubino et al. [38]. Ehgoetz
Martens et al. [28] characterized three unique phenotypes of
FOG using behavioural measures and neuroimaging of the
limbic corticostriatal pathway [28], Gilat et al. [42] demonstrated enhanced baseline striato-limbic connectivity in
freezers vs. nonfreezers [42], and Rubino et al. [38] found
evidence for volume loss in the posterior parietal cortex
contributing to FOG. Most pertinent to this literature review, HADS scores in the study of Ehgoetz Martens et al.
[28] were signiﬁcantly associated with increased coupling
between the limbic network and ventral striatum/cognitive
control network within the anxious subtype of FOG. Future
investigations should further ascertain the degree to which
anxiety impacts functional connectivity in FOG.

5. Conclusion
A growing body of literature has linked anxiety to the
presence, severity, and progression of FOG in PD patients,
adding a neuropsychiatric element to what was once thought
to be a solely motor phenomenon. The majority of the
observational studies in this literature review with anxiety as
a primary outcome relate anxiety to FOG, and these results
are supplemented by experimental paradigms where anxiety-inducing environments reliably elicit FOG, anxiety levels
signiﬁcantly predict response to pharmacological management of FOG, and anxiety levels predict speciﬁc FOG
phenotypes based on neuroimaging. A review of this literature reveals conﬂicting ﬁndings perhaps attributable to
variable and potentially suboptimal anxiety and FOG
measures in PD. Establishing a standardized anxiety scale
suitable for PD should be of primary importance in future
research on this topic. Recent successes with evoking FOG in
an experimental setting in tandem with self-reported
measures are encouraging. Future studies should incorporate both self-reported and objective assessments of
FOG. The latter should be investigated in settings that have
potential to induce FOG, increasing the frequency with
which this symptom can be observed. Furthermore, the
current state of evidence does not permit causal statements
regarding the relation between anxiety and FOG. Future
designs should aim to expose and critically test the nature of
this relation between these two variables. Understanding the
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determinants and underpinnings of FOG is important as this
could lead to novel treatment options for this relatively
intractable symptom that is minimally responsive to dopaminergic or surgical therapies.
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freezing in Parkinson’s disease: a survey of 6,620 patients,”
Movement Disorders, vol. 22, no. 7, pp. 953–956, 2007.
[7] N. Giladi, R. Kao, and S. Fahn, “Freezing phenomenon in
patients with Parkinsonian syndromes,” Movement Disorders,
vol. 12, no. 3, pp. 302–305, 1997.
[8] N. Giladi, H. Shabtai, E. S. Simon, S. Biran, J. Tal, and
A. D. Korczyn, “Construction of freezing of gait questionnaire
for patients with Parkinsonism,” Parkinsonism and Related
Disorders, vol. 6, no. 3, pp. 165–170, 2000.
[9] J. G. Nutt, B. R. Bloem, N. Giladi, M. Hallett, F. B. Horak, and
A. Nieuwboer, “Freezing of gait: moving forward on a
mysterious clinical phenomenon,” The Lancet Neurology,
vol. 10, no. 8, pp. 734–744, 2011.
[10] S. G. Lutz, J. D. Holmes, E. A. Ready, M. E. Jenkins, and
A. M. Johnson, “Clinical presentation of anxiety in Parkinson’s disease,” OTJR: Occupation, Participation and Health,
vol. 36, no. 3, pp. 134–147, 2016.
[11] A. S. Zigmond and R. P. Snaith, “The hospital anxiety and
depression scale,” Acta Psychiatrica Scandinavica, vol. 67,
no. 6, pp. 361–370, 1983.
[12] M. Hamilton, “The assessment of anxiety states by rating,”
British Journal of Medical Psychology, vol. 32, no. 1, pp. 50–55,
1959.
[13] M. Hamilton, “A rating scale for depression,” Journal of
Neurology, Neurosurgery and Psychiatry, vol. 23, no. 1,
pp. 56–62, 1960.
[14] A. T. Beck, N. Epstein, G. Brown, and R. A. Steer, “An inventory for measuring clinical anxiety: psychometric properties,” Journal of Consulting and Clinical Psychology, vol. 56,
no. 6, pp. 893–897, 1988.

23
[15] C. D. Spielberger, Manual for the State-Trait Anxiety Inventory (Form Y), Consulting Psychologists Press, Palo Alto,
CA, USA, 1983.
[16] C. Jenkinson, R. Fitzpatrick, and V. Peto, The Parkinson’s
Disease Questionnaire: User Manual for the PDQ-39, PDQ-8
and the PDQ Summary Index, University of Oxford Health
Services Research Unit, Oxford, UK, 1998.
[17] A. Nieuwboer, L. Rochester, T. Herman et al., “Reliability of
the new freezing of gait questionnaire: agreement between
patients with Parkinson’s disease and their carers,” Gait and
Posture, vol. 30, no. 4, pp. 459–463, 2009.
[18] H. Zhang, X. Yin, Z. Ouyang et al., “A prospective study of
freezing of gait with early Parkinson disease in Chinese patients,” Medicine, vol. 95, no. 26, p. e4056, 2016.
[19] K. A. E. Martens, J. M. Hall, M. Gilat, M. J. Georgiades,
C. C. Walton, and S. J. G. Lewis, “Anxiety is associated with
freezing of gait and attentional set-shifting in Parkinson’s
disease: a new perspective for early intervention,” Gait and
Posture, vol. 49, pp. 431–436, 2016.
[20] C. C. Walton, J. M. Shine, J. M. Hall et al., “The major impact
of freezing of gait on quality of life in Parkinson’s disease,”
Journal of Neurology, vol. 262, no. 1, pp. 108–115, 2015.
[21] R. Ou, X. Guo, W. Song et al., “Freezing of gait in Chinese
patients with Parkinson disease,” Journal of the Neurological
Sciences, vol. 345, no. 1-2, pp. 56–60, 2014.
[22] D. J. Burn, S. Landau, J. V. Hindle et al., “Parkinson’s disease
motor subtypes and mood,” Movement Disorders, vol. 27,
no. 3, pp. 379–386, 2012.
[23] A. Lieberman, “Are freezing of gait (FOG) and panic related?,” Journal of the Neurological Sciences, vol. 248, no. 1-2,
pp. 219–222, 2006.
[24] Z. Yao, Y. Shao, and X. Han, “Freezing of gait is associated
with cognitive impairment in patients with Parkinson disease,” Neuroscience Letters, vol. 656, pp. 126–130, 2017.
[25] F. Rahimi, A. C. Roberts, and M. Jog, “Patterns and predictors
of freezing of gait improvement following rasagiline therapy: a
pilot study,” Clinical Neurology and Neurosurgery, vol. 150,
pp. 117–124, 2016.
[26] K. A. Ehgoetz Martens, E. L. Lukasik, M. J. Georgiades et al.,
“Predicting the onset of freezing of gait: a longitudinal study,”
Movement Disorders, vol. 33, no. 1, pp. 128–135, 2018.
[27] R. Ou, Q. Wei, B. Cao et al., “Predictors of freezing of gait in
Chinese patients with Parkinson’s disease,” Brain and Behavior, vol. 8, no. 3, article e00931, 2018.
[28] K. A. Ehgoetz Martens, J. M. Hall, M. J. Georgiades et al., “The
functional network signature of heterogeneity in freezing of
gait,” Brain, vol. 141, no. 4, pp. 1145–1160, 2018.
[29] K. A. Ehgoetz Martens, J. M. Shine, C. C. Walton et al.,
“Evidence for subtypes of freezing of gait in Parkinson’s
disease,” Movement Disorders, vol. 33, no. 7, pp. 1174–1178,
2018.
[30] J. Vandenbossche, N. Deroost, E. Soetens et al., “Freezing of
gait in Parkinson disease is associated with impaired conﬂict
resolution,” Neurorehabilitation and Neural Repair, vol. 25,
no. 8, pp. 765–773, 2011.
[31] V. S. Kostic, F. Agosta, M. Pievani et al., “Pattern of brain
tissue loss associated with freezing of gait in Parkinson disease,” Neurology, vol. 78, no. 6, pp. 409–416, 2012.
[32] K. A. Ehgoetz Martens, C. G. Ellard, and Q. J. Almeida, “Does
anxiety cause freezing of gait in Parkinson’s disease?,” PLoS
One, vol. 9, no. 9, Article ID e106561, 2014.
[33] M. Pimenta, D. Moreira, T. Nogueira et al., “Anxiety independently contributes to severity of freezing of gait in

24

[34]

[35]

[36]

[37]

[38]

[39]

[40]

[41]

[42]

[43]

[44]

[45]

[46]

[47]

[48]

Parkinson’s Disease
people with Parkinson’s disease,” Journal of Neuropsychiatry
and Clinical Neurosciences, vol. 31, no. 1, pp. 80–85, 2018.
S. Perez-Lloret, L. Negre-Pages, P. Damier et al., “Prevalence,
determinants, and eﬀect on quality of life of freezing of gait in
Parkinson disease,” JAMA Neurology, vol. 71, no. 7,
pp. 884–890, 2014.
J. M. Hall, J. M. Shine, C. C. Walton et al., “Early phenotypic
diﬀerences between Parkinson’s disease patients with and
without freezing of gait,” Parkinsonism and Related Disorders,
vol. 20, no. 6, pp. 604–607, 2014.
Y. E. Huh, S. Hwang, K. Kim, W.-H. Chung, J. Youn, and
J. W. Cho, “Postural sensory correlates of freezing of gait in
Parkinson’s disease,” Parkinsonism and Related Disorders,
vol. 25, pp. 72–77, 2016.
A. Raﬀo De Ferrari, G. Lagravinese, E. Pelosin et al., “Freezing
of gait and aﬀective theory of mind in Parkinson disease,”
Parkinsonism and Related Disorders, vol. 21, no. 5, pp. 509–
513, 2015.
A. Rubino, F. Assogna, F. Piras et al., “Does a volume reduction of the parietal lobe contribute to freezing of gait in
Parkinson’s disease?,” Parkinsonism and Related Disorders,
vol. 20, no. 10, pp. 1101–1103, 2014.
J. Vandenbossche, N. Deroost, E. Soetens et al., “Impaired
implicit sequence learning in Parkinson’s disease patients
with freezing of gait,” Neuropsychology, vol. 27, no. 1,
pp. 28–36, 2013.
E. Heremans, E. Nackaerts, S. Broeder, G. Vervoort,
S. P. Swinnen, and A. Nieuwboer, “Handwriting impairments
in people with Parkinson’s disease and freezing of gait,”
Neurorehabilitation and Neural Repair, vol. 30, no. 10,
pp. 911–919, 2016.
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